

Supporting Information

A General Electron Donor–Acceptor Complex for Photoactivation of Arenes *via* Thianthrenation

Kai Sun,^[a] Anzai Shi,^[a] Yan Liu,^[b] Xiaolan Chen,*^[a] Panjie Xiang,^[a] Xiaotong Wang,^[a] Lingbo Qu,^[a] and Bing Yu*^[a]

^a*Green Catalysis Center, College of Chemistry, Zhengzhou University, Zhengzhou 450001, China. Email: chenxl@zzu.edu.cn; bingyu@zzu.edu.cn*

^b*Henan International Joint Laboratory of Rare Earth Composite Material, College of Materials Engineering, Henan University of Engineering, Zhengzhou 451191, China*

Table of Contents

1. General Information	3
1.1 Materials and instruments.....	3
1.2 General procedure for the synthesis of azauracil substrates	3
1.3 General procedure and characterization data for the synthesis of azauracil ribonucleoside	3
1.4 General procedure for the synthesis of quinoxalinone substrates	4
1.5 General procedure for the synthesis of aryl sulfonium salt substrates	5
1.6 The spectrum of the lamp and the visible-light irradiation instrument	5
2. Experimental procedures	6
2.1 General experimental procedures for the desired product.....	6
2.2 Additional attempts to decrease the donor loading	7
2.3 Unsuitable (hetero)aromatic cycles	7
2.4 Gram-scale synthesis	7
2.5 Irradiation with natural sunlight	8
2.6 One-pot sequence	9
2.7 Sensitivity assessment of reaction	10
2.8 Control experiment.....	11
2.9 Titration experiments.....	12


2.10 In vitro antitumor activity.....	13
2.11 Determination of the association constant (K_{DABCO})	13
2.12 Determination of binding stoichiometry of EDA complex	14
2.13 UV-vis absorbance experiment	15
3. Computational method	16
3.1 Computational Details	16
3.2 Coordinates of Stationary Points	16
4. Characterization Data for Products	18
5. NMR Copies of Products.....	55
6. Reference.....	161

1. General Information

1.1 Materials and instruments

All reagents were purchased from commercial suppliers, which were used directly without further purification unless otherwise stated. TLC was performed on silica gel plates (F254, 200-300 mesh) using UV light (254/366 nm) for detection. Products were purified by column chromatography, which was carried out on 200-300 mesh of silica gel purchased from Qing Dao Hai Yang Chemical Industry Co. All the ¹H, ¹³C, and ¹⁹F NMR spectra were recorded on Bruker Avance 400 MHz operating at 400 MHz, 101 MHz, and 376 MHz, respectively. Proton chemical shifts δ were given in ppm using tetramethylsilane as internal standard. All NMR spectra were recorded in CDCl₃ or DMSO-d₆ at room temperature (20 ± 3 °C). High-resolution mass spectra (HRMS) were taken with a 3000-mass spectrometer, using Waters Q-Tof MS/MS system with the ESI technique. Absorption spectra were recorded on an Agilent 8453.


1.2 General procedure for the synthesis of azauracil substrates^[1]



Alkyl halides (3.6 mmol, 0.9 equiv.) was added dropwise to a stirring solution of 6-azuracil (4.0 mmol, 1.0 equiv.), K₂CO₃ (2.0 mmol, 0.5 equiv.) in DMF (40 mL). The reaction mixture was allowed to stir at room temperature for 16 h. Then, the mixture was quenched with saturated Na₂CO₃ solution and extracted with DCM for three times. The organic layers were combined, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude products were purified through silica gel column chromatography using petroleum ether/ethyl acetate as eluent to give to afford the corresponding *N*-1-alkyl-6-azauracils.

Alkyl halides (2.0 mmol, 1.0 equiv.) was added dropwise to a stirring solution of *N*-1-alkyl-6-azauracils (2.0 mmol, 1.0 equiv.), K₂CO₃ (1.0 mmol, 0.5 equiv.) in DMF (20 mL). The reaction mixture was allowed to stir at room temperature for 16 h. Then, the mixture was quenched with saturated Na₂CO₃ solution and extracted with DCM for three times. The organic layers were combined, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude products were purified through silica gel column chromatography using petroleum ether/ethyl acetate as eluent to give to afford the corresponding *N*-1,*N*-3-dialkyl-6- azauracils.

1.3 General procedure and characterization data for the synthesis of azauracil ribonucleoside^[1]




Triphosgene (653.4 mg, 2.2 mmol, 0.4 equiv.) was added dropwise to a stirring solution of (2R,3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-ol (2.31 g, 5.5 mmol, 1.0 equiv.) in THF (24 mL) under N₂ atmosphere. The mixture was allowed to stir at 10~15 °C for 2 minutes. Pyridine (0.55 mL) was added dropwise over 20 minutes at 10~15 °C. The reaction mixture was allowed to stir at room temperature for 4 h. The reaction mixture was filtered and the solid residue was discarded. The crude chloride obtained as a solution in THF was used immediately for the coupling reaction.

To an oven-dried round bottom flask charged with crude chloride obtained (1.78 g, 5.0 mmol, 1.0 equiv., 24 mL solution in anhydrous THF) and 3,5-bis(trimethylsilyloxy)-1,2,4-triazine (1.67 g, 6.5 mmol, 1.3 equiv.) was added SnCl₄ (3.8 mL, 3.75 mmol, 0.75 equiv., 1 mol/L solution in CH₂Cl₂) dropwise at 0 °C under N₂ atmosphere. The reaction mixture was allowed to stir at room temperature for 12 h. The reaction was quenched with an aqueous NaHCO₃ solution and the mixture was extracted with EtOAc. The organic extracts were combined, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash chromatography (*n*-hexane/EtOAc = 4:1) to afford azauracil ribonucleoside in 25% yield as a pale yellow viscous liquid.

MeI (2.0 mmol, 1.0 equiv.) was added dropwise to a stirring solution of azauracil ribonucleoside (2.0 mmol, 1.0 equiv.), K₂CO₃ (1.0 mmol, 0.5 equiv.) in DMF (20 mL). The reaction mixture was allowed to stir at room temperature for 16 h. Then, the mixture was quenched with saturated Na₂CO₃ solution and extracted with DCM for three times. The organic layers were combined, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude products were purified through silica gel column chromatography using petroleum ether/ethyl acetate as eluent to give to afford the corresponding *N*-Methyl azauracil ribonucleoside.


1.4 General procedure for the synthesis of quinoxalinone substrates^[2]



Ethyl glyoxalate (1.1 equiv.) was added dropwise to a stirring solution of *o*-arylenediamine (1 equiv.) in ethanol. The reaction mixture was allowed to stir at room temperature for 1 h. The precipitated solid was filtered and washed with ethanol, then dried to give quinoxalinone.

To a suspension of quinoxalinone (1 equiv.) in DMF was added potassium carbonate (1.2 equiv.) and the corresponding halogenoalcane (1.6 equiv.). The mixture was stirred at room temperature overnight. Ethyl acetate and water were added. The aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with a saturated solution of NaCl, dried over MgSO₄, filtered and evaporated under reduced pressure. The residue is purified by flash chromatography over silica gel to afford the desired product *N*-alkyl quinoxalinone.

1.5 General procedure for the synthesis of aryl sulfonium salt substrates^[3]



Under an ambient atmosphere, a 20 mL glass vial was charged with arene (0.50 mmol, 1.0 equiv.) and dry MeCN (4.0 mL). After cooling to 0 °C, HBF₄·OEt₂ (1.5 equiv.) was added to the vial while stirring the reaction mixture. After all solids were dissolved, thianthrenium-S-oxide (TTO) (0.50 mmol, 1.0 equiv.) was added in one portion to the solution at 0 °C, leading to a suspension. Subsequently, trifluoroacetic anhydride (1.5 mmol, 3.0 equiv.) was added in one portion at 0 °C, resulting in a color change to deep purple. The vial was sealed with a screw cap. The mixture was stirred at 0 °C for 1 h, subsequently the reaction mixture was warmed to 25 °C and stirred until all solids dissolved, and the intensity of the purple color decreased. The solution was poured onto a mixture of 20 mL dichloromethane, 20 mL saturated aqueous Na₂CO₃ solution, and 10 mL water. After stirring for 5 min at 25 °C, the mixture was poured into a separatory funnel, and the layers were separated. The dichloromethane layer was washed with aqueous NaBF₄ solution (2 × ca. 20 mL, 5 % w/w) and with water (2 × ca. 20 mL). The collected organic layers were then dried over MgSO₄, then filtered and concentrated under reduced pressure and purified by precipitation with Et₂O/DCM, and then repeated the precipitation procedure 3 times, the solid was dried in vacuo to afford the aryl sulfonium salts.

1.6 The spectrum of the lamp and the visible-light irradiation instrument

Photochemical reaction was carried out under visible light irradiation by a blue LED at 25 °C. RLH-18 8-position Photo Reaction System manufactured by Beijing Roger Tech Ltd. was used in this system. Eight 10 W blue LEDs were equipped in this Photo reactor. The blue LED's energy peak wavelength is 430 nm, peak width at half-height is 18.4 nm, lirradiance@10 W is 237.57 mW/cm². The reaction vessel is borosilicate glass test tube and the distance between it

and the lamp is 15 mm, no filter applied.





Figure S1. The spectrum of our lamp (white LED)



Figure S2. The visible-light irradiation instrument

2. Experimental procedures

2.1 General experimental procedures for the desired product



The mixture of azauracil (0.1 mmol), aryl sulfonium salt (0.2 mmol, 2 equiv.), DABCO (0.3 mmol, 3 equiv.) and CH₃CN (1.5 mL) were sequentially added in a 25 mL reaction vessel. Then the reaction vessel was irradiated with 10 W blue LED (430 nm) at room temperature under N₂ atmosphere for 12 h. After the reaction, the solvent was evaporated under vacuum. The reaction was quenched with aqueous NaHCO₃ solution and the mixture was extracted with EtOAc. The organic extracts were combined, dried over Na₂SO₄, and concentrated under reduced pressure. The crude products were purified by silica gel chromatography using petroleum ether/ethyl acetate as eluting solvent to give the desired products.



The mixture of quinoxalinone (0.1 mmol), aryl sulfonium salt (0.2 mmol, 2 equiv.), DABCO (0.3 mmol, 3 equiv.) and CH₃CN (1.5 mL) were sequentially added in a 25 mL reaction vessel. Then the reaction vessel was irradiated with 10 W blue LED (430 nm) at room temperature under N₂ atmosphere for 12 h. After the reaction, the solvent was evaporated under vacuum. The reaction was quenched with aqueous NaHCO₃ solution and the mixture was extracted with EtOAc. The organic extracts were combined, dried over Na₂SO₄, and concentrated under reduced pressure. The crude products were purified by silica gel chromatography using petroleum ether/ethyl acetate as eluting solvent to give the desired products.


2.2 Additional attempts to decrease the donor loading

Table S1. Reactions with a catalytic amount of DABCO^a

Entry	Base (2 equiv.)	Yield (%)		
			1	2
1	K ₂ CO ₃	41		
2	Cs ₂ CO ₃	32		
3	K ₃ PO ₄	52		
4	CH ₃ COONa	23		
5	K ₂ HPO ₄	61		
6	NaHCO ₃	20		
7	KOH	66		
8 ^[b]	KOH	51		
9 ^[c]	KOH	27		
10 ^[d]	KOH	0		

^[a]Reaction conditions: **1** (0.1 mmol), **2** (0.2 mmol), DABCO (30 mol%), base (2 equiv.), and CH₃CN (1.5 mL) were irradiated with 10 W blue LED (430 nm) at room temperature under N₂ atmosphere for 12 h. Yields were given by ¹H NMR using 1,1,2,2-tetrachloroethane as an internal standard based on **1**. ^[b] 20 mol% DABCO was used. ^[c] 10 mol% DABCO was used. ^[d] In the absence of DABCO.


2.3 Unsuitable (hetero)aromatic cycles



Scheme S1. Unsuitable (hetero)aromatic cycles


2.4 Gram-scale synthesis

The mixture of 2,4-dibenzyl-1,2,4-triazine-3,5(2H,4H)-dione (4 mmol), methylbenzene-derived sulfonium salt (8 mmol), DABCO (12 mmol) and CH₃CN (30 mL) were sequentially added in a 100 mL round bottom flask. And then the reaction system was carried out under 40 W blue LED (430 nm) at room temperature under N₂ atmosphere for 16 h. After reaction, the residue was quenched with saturated NaHCO₃ solution (10 mL), and ethyl acetate (15 mL) was added three times for extraction. The combined organic layers were dried over anhydrous Na₂SO₄. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 30/1) to afford the desired product (0.97 g, 63%).




Scheme S2. Gram-scale synthesis of **3**

The mixture of 1-methylquinoxalin-2(1H)-one (5 mmol), methylbenzene-derived sulfonium salt (10 mmol), DABCO (15 mmol) and CH₃CN (30 mL) were sequentially added in a 100 mL round bottom flask. And then the reaction system was carried out under 40 W blue LED (430 nm) at room temperature under N₂ atmosphere for 16 h. After reaction, the residue was quenched with saturated NaHCO₃ solution (10 mL), and ethyl acetate (15 mL) was added three times for extraction. The combined organic layers were dried over anhydrous Na₂SO₄. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 20/1) to afford the desired product (0.98 g, 78%).



Scheme S3. Gram-scale synthesis of **41**


2.5 Irradiation with natural sunlight



Scheme S4. Synthesis of **3** under natural sunlight

The mixture of azauracil (0.1 mmol), aryl sulfonium salt (0.2 mmol, 2 equiv.), DABCO (0.3 mmol, 3 equiv.) and CH₃CN (1.5 mL) were sequentially added in a 25 mL reaction vessel. Then the reaction system was carried out under sunlight for 12 h (from 11:00 to 16:00;


2021/06/04 and from 10:00 to 17:00; 2021/06/05. Zhengzhou, Henan province, China. Temperature: 25 °C – 29 °C). After the reaction, the solvent was evaporated under vacuum. The reaction was quenched with aqueous NaHCO₃ solution and the mixture was extracted with EtOAc. The organic extracts were combined, dried over Na₂SO₄, and concentrated under reduced pressure. The crude products were purified by silica gel chromatography using petroleum ether/ethyl acetate as eluting solvent to give the desired products.



Scheme S5. Synthesis of **41** under natural sunlight

The mixture of quinoxalinone (0.1 mmol), aryl sulfonium salt (0.2 mmol, 2 equiv.), DABCO (0.3 mmol, 3 equiv.) and CH₃CN (1.5 mL) were sequentially added in a 25 mL reaction vessel. Then the reaction system was carried out under sunlight for 12 h (from 11:00 to 16:00; 2021/06/04 and from 10:00 to 17:00; 2021/06/05. Zhengzhou, Henan province, China. Temperature: 25 °C – 29 °C). After similar operation, the crude products were purified by silica gel chromatography using petroleum ether/ethyl acetate as eluting solvent to give the desired products.


2.6 One-pot sequence



Under an ambient atmosphere, a 20 mL glass vial was charged with toluene (18.5 mg, 0.2 mmol) and MeCN (0.5 mL, c = 0.4 M). After cooling to 0 °C, HBF₄·OEt₂ (1.5 equiv.) was added to the vial while stirring the reaction mixture. After all solids were dissolved, thianthrenium-S-oxide (TTO) (0.2 mmol, 1.0 equiv.) was added in one portion to the solution at 0 °C, leading to a suspension. Subsequently, trifluoroacetic anhydride (0.6 mmol, 3.0 equiv.) was added in one portion at 0 °C, resulting in a color change to deep purple. The vial was sealed with a screw cap. The mixture was stirred at 0 °C for 1 h. Subsequently, the reaction mixture was warmed to 25 °C and stirred until all solids dissolved, and the intensity of the purple color decreased. Then K₂CO₃ (82.9 mg, 0.6 mmol) was added and stirred for five minutes. Afterward, 2,4-dibenzyl-1,2,4-triazine-3,5(2H,4H)-dione **1** (0.1 mmol, 29.3 mg), DABCO (33.7 mg, 0.3 mmol) and


CH_3CN (1.5 mL) were added in the 25 mL reaction vial. Then the reaction vessel was irradiated with 10 W blue LED (430 nm) at room temperature under N_2 atmosphere for 24 h. After the reaction, the solvent was evaporated under vacuum. The crude product was purified by silica gel chromatography to give the desired product **3** in 37% yield.

2.7 Sensitivity assessment of reaction



Parameter	Variation	Description	Yield ^b	
Concentration (<i>c</i>)	High <i>c</i>	<i>c</i> + 10% <i>c</i> 1.35 mL CH_3CN	79%	
	Low <i>c</i>	<i>c</i> - 10% <i>c</i> 1.65 mL CH_3CN	75%	
H ₂ O level	High H ₂ O	+ H ₂ O; V _{H2O} = 15 μL H ₂ O in 1.5 mL CH ₃ CN	73%	
O ₂ level	High O ₂	O ₂ balloon	O ₂ balloon instead of air	40%
Temperature (<i>T</i>)	High <i>T</i>	<i>T</i> + 10 °C	35 °C	78%
	Low <i>T</i>	<i>T</i> - 10 °C	15 °C	73%
Light intensity (<i>W</i>)	Low <i>W</i>	<i>W</i> /16	0.6 W	0%
Scale	Big scale	n·30	3 mmol of 1a	70%

^aStandard conditions: 2,4-dibenzyl-1,2,4-triazine-3,5(2H,4H)-dione (0.1 mmol), methylbenzene-derived sulfonium salt (0.2 mmol), DABCO (3 equiv), CH_3CN (1.5 mL), 430 nm blue LED (10 W), under N_2 for 12 h, room temperature. ^bThe average yield of three parallel reactions. ^cDeviation from the yield of standard reaction.



Parameter	Variation	Description	Yield ^b	
Concentration (<i>c</i>)	High <i>c</i>	<i>c</i> + 10% <i>c</i> 1.35 mL CH_3CN	80%	
	Low <i>c</i>	<i>c</i> - 10% <i>c</i> 1.65 mL CH_3CN	78%	
base dosage	High base	+ 1 equiv	4 equiv	76%
	Low base	- 1 equiv	2 equiv	56%
H ₂ O level	High H ₂ O	+ H ₂ O; V _{H2O} = 15 μL H ₂ O in 1.5 mL CH ₃ CN	78%	
O ₂ level	High O ₂	O ₂ balloon	O ₂ balloon instead of air	32%
Temperature (<i>T</i>)	High <i>T</i>	<i>T</i> + 10 °C	35 °C	83%
	Low <i>T</i>	<i>T</i> - 10 °C	15 °C	74%
Light intensity (<i>W</i>)	Low <i>W</i>	<i>W</i> /16	0.6 W	0%
Scale	Big scale	n·30	3 mmol of 1a	68%

^aStandard conditions: 1-methylquinoxalin-2(1H)-one (0.1 mmol), methylbenzene-derived sulfonium salt (0.2 mmol), DABCO (3 equiv), CH₃CN (1.5 mL), 430 nm blue LED (10 W), under N₂ for 12 h, room temperature.
^bThe average yield of three parallel reactions. ^cDeviation from the yield of standard reaction.

2.8 Control experiment



Additive	Yield for 3	Detected by HRMS
TEMPO	23%	 101
1,1-Diphenylethyne	0%	 102
CuCl	trace	m/z: [M+H] ⁺ Calcd for C ₁₆ H ₂₆ NO ⁺ 248.2009 Found 248.2015

Scheme S6. Control experiments




Figure S3. The HRMS analysis of compound 101





Figure S4. The HRMS analysis of compound **102**



Scheme S7. Control experiments

2.9 Titration experiments

¹H NMR spectra of mixtures of methylbenzene-derived sulfonium salt **2** and DABCO in CDCl₃ were recorded at 298 K. In an NMR tube, the total volume of the mixture was 0.6 mL, the concentration of methylbenzene-derived sulfonium salt (0.03 mmol) was kept constant at 0.05 M, and that of TMEDA was varied from 0 to 1.5 M. The molar ratios of methylbenzene-derived sulfonium salt : DABCO were 1:0, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:10, 1:20, 1:30. CDCl₃ ($\delta = 7.2600$) was used as an internal standard. The ¹H NMR signal of ArH in methylbenzene-

derived sulfonium salt **2** shifted upfield along with increasing the amount of DABCO, indicating the formation of EDA complex of methylbenzene-derived sulfonium salt with DABCO.




Figure S5. ^1H NMR shift of methylbenzene-derived sulfonium salt with DABCO.

2.10 In vitro antitumor activity




Figure S6. The in vitro antitumor activity of 37 and 92 against Ramos cells

2.11 Determination of the association constant (K_{DABCO})

^1H NMR for each sample was recorded and the changes of chemical shift ($\Delta\delta$) for ArH in methylbenzene-derived sulfonium salt were used to draw the plot. The association constant of methylbenzene-derived sulfonium salt with DABCO (K_{DABCO}) was calculated: $K_{\text{DABCO}} = c/a = 7.5589/7.3010 = 1.04 \text{ M}^{-1}$

Entry	[sulfonium salt]	1/[DABCO]	δ (ppm)	$\Delta\delta$ (ppm)	1/ $\Delta\delta$ (ppm)
1	0.05	--	7.2082	--	--
2	0.05	20	7.2013	0.0069	144.9275362
3	0.05	10	7.198	0.0102	98.03921569
4	0.05	6.67	7.1903	0.0179	55.86592179
5	0.05	5	7.187	0.0212	47.16981132
6	0.05	4	7.1795	0.0287	34.84320557
7	0.05	3.33	7.1776	0.0306	32.67973856
8	0.05	2	7.1613	0.0469	21.32196162
9	0.05	1	7.1101	0.0981	10.19367992
10	0.05	0.67	7.0754	0.1328	7.530120482




Figure S7. Plot for determination of the association constant (K_{DABCO})

2.12 Determination of binding stoichiometry of EDA complex

The binding stoichiometry between methylbenzene-derived sulfonium salt and DABCO was evaluated using Job's plot analysis: ^1H NMR spectra of mixtures of methylbenzene-derived sulfonium salt and DABCO in CDCl_3 were recorded at 298 K. CDCl_3 ($\delta = 7.2600$) was used as an internal standard. The total volume of the mixture was 0.5 mL, and the total amount of methylbenzene-derived sulfonium salt and DABCO was kept constant at 0.1 mmol (0.2 M), while the amount of methylbenzene-derived sulfonium salt was varied from 0 to 0.1 mmol (0-0.2 M). The molar ratios of [methylbenzene-derived sulfonium salt]/[methylbenzene-derived sulfonium salt + DABCO] were 0.0, 0.2, 0.4, 0.5, 0.6, 0.8, 1.0. ^1H NMR for each sample was recorded and the changes of chemical shift ($\Delta\delta$) for ArH in methylbenzene-derived sulfonium salt were used to draw the plot. The stoichiometry was determined by plotting ratios of [methylbenzene-derived sulfonium salt] \times $\Delta\delta$ against ratios of [methylbenzene-derived sulfonium salt]/[methylbenzene-derived sulfonium salt + DABCO] to afford a maximum value.

$X_{\max} = b/(-2a) = 0.00149/(-2) \times (-0.00153) \approx 0.5$. These data indicate that the formation of EDA complex of methylbenzene-derived sulfonium salt with DABCO in a binding stoichiometry of 1:1.




Figure S8. Job's plot

2.13 UV-vis absorbance experiment

A UV-vis absorbance experiment has been carried out for confirming the formation of EDA complex as illustrated below in Figure S9. In Figure S9, the red UV absorbance line came from compound **2** solution, the blue one came from DABCO solution, and the black one came from the mixed solution of compound **2** and DABCO. UV-vis spectra revealed that upon mixing compound **2** with DABCO, an obvious bathochromic shift of the UV-vis absorbance was observed, strongly suggesting that compound **2**-DABCO EDA complex might indeed be formed in the mixed solution.




Figure S9. UV-vis absorption spectra. Red line: compound **2** (0.1 mmol) in 2 mL MeCN; Blue line: DABCO (0.1 mmol) in 2 mL MeCN; Black line: compound **2** (0.1 mmol) and DABCO (0.1 mmol) in 2 mL MeCN.

3. Computational method

3.1 Computational Details

In this work, we used Gaussian 16 software^[1] for all calculations within the framework of DFT. All the molecular structures were computed with the B3LYP (Becke, three-parameter, Lee–Yang–Parr) hybrid functional^[2] to describe the exchange–correlation energies. DFT-D3(BJ) method was considered in this work to calculate the weak interaction between methylbenzene-derived sulfonium salt **2** and DABCO.^[3] Basis sets were employed for high-level B3LYP calculations at 6-31+G(d,p)^[4] was adopted for atoms including C, N, S, and H. Vibrational frequency calculations were performed on all minima states, and each minima was identified to have no imaginary frequencies. The population analysis has also been performed by the natural bond orbital method.^[5,6]

[1] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2016.

[2] Devlin, F. J.; Finley, J. W.; Stephens, P. J.; Frisch, M. J. Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields: A Comparison of Local, Nonlocal, and Hybrid Density Functionals. *J. Phys. Chem.* 1995, 99, 16883– 16902, DOI: 10.1021/j100046a014


[3] JCP,132,154104(2010)

[4] McLean, A. D.; Chandler, G. S. Contracted Gaussian basis sets for molecular calculations. I. Second row atoms, Z=11–18. *J. Chem. Phys.* 1980, 72, 5639– 5648, DOI: 10.1063/1.438980

[5] A.E. Reed, L.A. Curtiss, F. Weinhold, *Chem. Rev.* 88, 899 (1988).

[6] E.D. Glendening, A.E. Reed, J.E. Carpenter, F. Weinhold, *J. Am. Chem. Soc.* 120, 12051 (1998).

3.2 Coordinates of Stationary Points




C	-3.89655600	-2.59927600	-2.58700800
C	-4.03645800	-2.31617500	-1.22781300
C	-3.03840900	-1.60551300	-0.54599000
C	-1.91138000	-1.18722000	-1.27225300
C	-1.74600200	-1.50251600	-2.62662700
C	-2.75070100	-2.20741100	-3.28715700
C	-0.47430600	-0.97098700	1.11682300
C	-1.61519900	-1.39607500	1.81863100
C	-1.43581200	-1.93743500	3.09812800
H	-2.29731900	-2.29039300	3.65600200
C	-0.15352500	-2.04700500	3.64011700
C	0.96988900	-1.64734600	2.91035400
C	0.82022900	-1.10848000	1.63120400
H	-4.67913800	-3.15250800	-3.09638700
H	-4.90975400	-2.66388400	-0.68512300
H	-0.85002200	-1.19057500	-3.15459200
H	-2.63850700	-2.44993700	-4.33836300
H	-0.03341600	-2.47068700	4.63228300
H	1.96315800	-1.75471900	3.33308200
H	1.68934500	-0.78660700	1.04826700
S	-3.27327800	-1.26331900	1.18344600
S	-0.63109700	-0.21117300	-0.49440200
C	-1.42487700	1.40229900	-0.17095000
C	-1.06291800	2.11937100	0.96915000
C	-2.26078700	1.95053700	-1.14469800
C	-1.57676200	3.40565900	1.14075500
H	-0.40511000	1.69398700	1.71951700
C	-2.76036300	3.23812900	-0.94897200
H	-2.53415400	1.39395500	-2.03496800
C	-2.43229100	3.98683000	0.19251100

H	-1.30330700	3.96419400	2.03123300
H	-3.41725700	3.66539500	-1.70118000
C	-3.00282900	5.36700100	0.40270000
H	-3.98711800	5.30778500	0.88300200
H	-2.35921900	5.97283100	1.04575300
H	-3.13376700	5.89387200	-0.54652800
C	6.04027500	-0.52791300	0.14451000
H	6.54899800	-1.43834700	-0.18934600
H	6.68766400	-0.04210700	0.88207500
C	5.06575000	-0.27993500	-2.03291800
H	4.99286900	0.39024900	-2.89622700
H	5.57820100	-1.18888400	-2.36539700
C	5.24701900	1.61844600	-0.57686700
H	5.89139200	2.10305900	0.16418700
H	5.17793000	2.28926100	-1.43991400
C	4.63120600	-0.84905600	0.74522700
H	4.55567200	-0.51861400	1.78794400
H	4.41927900	-1.92441700	0.72146400
C	3.83297100	1.30262700	0.01584600
H	3.75237400	1.62736600	1.05979000
H	3.03947900	1.80618500	-0.54931900
N	5.89971700	0.37284900	-1.01135700
N	3.57587300	-0.15580500	-0.03214900
C	3.65342700	-0.60558100	-1.44123600
H	3.44515400	-1.68176500	-1.46588700
H	2.85791100	-0.09997100	-2.00232100

4. Characterization Data for Products


1,3-dibenzyl-6-(p-tolyl)-1,3,5-triazine-2,4(1H,3H)-dione (3)



White solid (31.4 mg, 82%); m.p. 130.5 – 132.1 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.90 (d, *J* = 8.2 Hz, 2H), 7.59 – 7.54 (m, 2H), 7.53 – 7.48 (m, 2H), 7.41 – 7.25 (m, 8H), 5.23 (s, 2H), 5.20 (s, 2H), 2.42 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 155.5, 148.8, 141.3, 140.3,


135.70, 135.68, 129.6, 129.3, 129.0, 128.82, 128.76, 128.6, 128.33, 128.28, 128.1, 55.7, 44.5, 21.4. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₂₄H₂₂N₃O₂, 384.1707; Found: 384.1718.

2,4-dibenzyl-6-phenyl-1,2,4-triazine-3,5(2H,4H)-dione (4)




White solid (26.6 mg, 72%); m.p. 151.1 – 152.4 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.04 – 7.94 (m, 2H), 7.60 – 7.55 (m, 2H), 7.53 – 7.44 (m, 5H), 7.43 – 7.32 (m, 6H), 5.23 (d, *J* = 15.5 Hz, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 155.5, 148.8, 141.2, 135.6, 135.6, 132.0, 130.0, 129.6, 128.84, 128.79, 128.6, 128.4, 128.33, 128.28, 128.1, 55.8, 44.5. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₂₃H₂₀N₃O₂, 370.1550; Found: 370.1559.

2,4-dibenzyl-6-(4-methoxyphenyl)-1,2,4-triazine-3,5(2H,4H)-dione (5)



White solid (30.3 mg, 76%); m.p. 114.3 – 115.1 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.00 (d, *J* = 9.0 Hz, 2H), 7.59 – 7.54 (m, 2H), 7.49 (d, *J* = 6.5 Hz, 2H), 7.41 – 7.33 (m, 6H), 6.97 (d, *J* = 9.0 Hz, 2H), 5.21 (d, *J* = 11.7 Hz, 4H), 3.87 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 161.1, 155.6, 148.8, 140.9, 135.7, 134.5, 129.9, 129.5, 128.80, 128.76, 128.6, 128.3, 128.1, 124.6, 113.7, 55.6, 55.4, 44.4. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₂₄H₂₂N₃O₃, 400.1656; Found: 400.1661.


1,3-dibenzyl-6-(4-cyclopropylphenyl)-1,3,5-triazine-2,4(1*H*,3*H*)-dione (6)



White solid (22.9 mg, 56%); m.p. 107.4 – 108.9 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.90 (d, *J* = 8.4 Hz, 2H), 7.59 – 7.54 (m, 2H), 7.52 – 7.45 (m, 2H), 7.42 – 7.30 (m, 6H), 7.14 (d, *J* = 8.4 Hz, 2H), 5.21 (d, *J* = 12.4 Hz, 4H), 1.99 – 1.92 (m, 1H), 1.09 – 1.00 (m, 2H), 0.81 – 0.73


(m, 2H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.5, 148.8, 146.6, 141.2, 135.70, 135.67, 129.6, 129.1, 128.83, 128.76, 128.6, 128.34, 128.28, 128.1, 125.4, 55.7, 44.4, 15.5, 9.8. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₂₄N₃O₂, 410.1863; Found: 410.1864.

2,4-dibenzyl-6-(4-(tert-butyl)phenyl)-1,2,4-triazine-3,5(2*H*,4*H*)-dione (7)




White solid (31.9 mg, 75%); m.p. 159.0 – 159.4 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.94 – 7.89 (m, 2H), 7.57 – 7.55 (m, 2H), 7.50 – 7.46 (m, 4H), 7.41 – 7.30 (m, 6H), 5.21 (d, *J* = 11.2 Hz, 4H), 1.36 (s, 9H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.6, 153.3, 148.8, 141.3, 135.68, 135.66, 129.6, 129.2, 128.8, 128.7, 128.6, 128.3, 128.2, 128.1, 125.3, 55.7, 44.5, 34.8, 31.2. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₇H₂₈N₃O₂, 426.2176; Found: 426.2180.

1,3-dibenzyl-6-(3,4-dimethylphenyl)-1,3,5-triazine-2,4(1*H*,3*H*)-dione (8)



White solid (30.9 mg, 78%); m.p. 115.9 – 117.1 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.76 (s, 1H), 7.72 (d, *J* = 7.9 Hz, 1H), 7.59 – 7.54 (m, 2H), 7.52 – 7.47 (m, 2H), 7.41 – 7.30 (m, 6H), 7.22 (d, *J* = 7.9 Hz, 1H), 5.21 (d, *J* = 14.3 Hz, 4H), 2.34 (d, *J* = 5.3 Hz, 6H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.6, 148.8, 141.5, 139.0, 136.5, 135.72, 135.70, 129.62, 129.58, 129.5, 129.4, 128.8, 128.7, 128.6, 128.3, 128.1, 126.0, 55.7, 44.4, 19.9, 19.8. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₄N₃O₂, 398.1863; Found: 398.1874.


***N*-(4-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenyl)benzamide (9)**



White solid (23.7 mg, 48%); m.p. 142.1 – 143.4 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.12


(s, 1H), 8.06 (d, $J = 8.7$ Hz, 2H), 7.88 (d, $J = 7.3$ Hz, 2H), 7.75 (d, $J = 8.7$ Hz, 2H), 7.58 – 7.54 (m, 3H), 7.50 – 7.46 (m, 4H), 7.41 – 7.31 (m, 6H), 5.20 (d, $J = 19.7$ Hz, 4H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 165.8, 155.5, 148.8, 140.4, 139.7, 135.62, 135.59, 134.7, 132.0, 129.5, 129.3, 128.9, 128.8, 128.6, 128.3, 128.1, 128.0, 127.1, 119.5, 55.7, 44.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₀H₂₅N₄O₃, 489.1921; Found: 489.1924.

1,3-dibenzyl-6-(4-bromophenyl)-1,3,5-triazine-2,4(1H,3H)-dione (10)




White solid (19.6 mg, 44%); m.p. 149.8 – 151.0 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.94 – 7.88 (m, 2H), 7.59 – 7.54 (m, 4H), 7.50 – 7.46 (m, 2H), 7.42 – 7.32 (m, 6H), 5.21 (d, $J = 17.4$ Hz, 4H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.3, 148.7, 140.1, 135.5, 135.4, 131.5, 130.9, 129.9, 129.6, 128.84, 128.83, 128.6, 128.4, 128.2, 124.6, 55.8, 44.6. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₃H₁₉BrN₃O₂, 448.0655; Found: 448.0670.

2,4-dibenzyl-6-(4-iodophenyl)-1,2,4-triazine-3,5(2H,4H)-dione (11)



White solid (28.2 mg, 57%); m.p. 112.7 – 113.9 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.83 – 7.72 (m, 4H), 7.54 (dd, $J = 7.7, 1.6$ Hz, 2H), 7.47 (dd, $J = 7.8, 1.5$ Hz, 2H), 7.42 – 7.32 (m, 6H), 5.20 (d, $J = 17.1$ Hz, 4H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.2, 148.7, 140.2, 137.5, 135.5, 135.4, 131.5, 129.9, 129.6, 128.84, 128.82, 128.6, 128.4, 128.2, 96.8, 55.8, 44.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₃H₁₉IN₃O₂, 496.0516; Found: 496.0518.


5-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-2-methoxybenzaldehyde (12)



White solid (23.1 mg, 54%); m.p. 89.2 – 89.9 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 10.50


(s, 1H), 8.49 (d, $J = 2.4$ Hz, 1H), 8.30 (dd, $J = 8.9, 2.4$ Hz, 1H), 7.55 (dd, $J = 7.8, 1.5$ Hz, 2H), 7.48 (dd, $J = 7.9, 1.4$ Hz, 2H), 7.40 – 7.31 (m, 6H), 7.06 (d, $J = 8.9$ Hz, 1H), 5.21 (d, $J = 18.9$ Hz, 4H), 4.01 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 189.2, 162.7, 155.4, 148.7, 139.8, 135.8, 135.53, 135.50, 129.5, 129.1, 128.82, 128.79, 128.6, 128.3, 128.1, 124.9, 124.6, 111.4, 55.9, 55.8, 44.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₂N₃O₄, 428.1605; Found: 428.1613.

2,4-dibenzyl-6-(4-fluorophenyl)-1,2,4-triazine-3,5(2*H*,4*H*)-dione (13)




White solid (21.3 mg, 55%); m.p. 124.1 – 125.2 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.07 – 7.99 (m, 2H), 7.59 – 7.54 (m, 2H), 7.49 (d, $J = 6.5$ Hz, 2H), 7.42 – 7.31 (m, 6H), 7.13 (t, $J = 8.7$ Hz, 2H), 5.22 (d, $J = 15.4$ Hz, 4H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 163.8 (d, $J = 250.8$ Hz), 155.4, 148.7, 140.2, 135.5 (d, $J = 2.3$ Hz), 130.5, 130.4, 129.6, 128.8, 128.6, 128.4, 128.1, 115.5, 115.2, 55.7, 44.5. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -110.27. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₃H₁₉FN₃O₂, 388.1456; Found: 388.1460.

2,4-dibenzyl-6-(4-(2,5-dioxopyrrolidin-1-yl)phenyl)-1,2,4-triazine-3,5(2*H*,4*H*)-dione (14)




White solid (31.8 mg, 68%); m.p. 92.7 – 93.1 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.16 (d, $J = 8.6$ Hz, 2H), 7.57 – 7.54 (m, 2H), 7.50 – 7.47 (m, 2H), 7.42 – 7.32 (m, 8H), 5.23 (s, 2H), 5.19 (s, 2H), 2.93 (d, $J = 6.0$ Hz, 4H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 175.9, 155.3, 148.7, 140.0, 135.5, 135.4, 133.2, 132.1, 129.6, 129.2, 128.9, 128.8, 128.6, 128.4, 128.1, 126.1, 55.8, 44.5, 28.4. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₇H₂₃N₄O₄, 467.1714; Found: 467.1712.

5-(1,5-dibenzyl-4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazin-2-yl)-2-methoxybenzonitrile (15)




White solid (22.6 mg, 53%); m.p. 169.6 – 170.4 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.38 – 8.24 (m, 2H), 7.58 – 7.52 (m, 2H), 7.50 – 7.45 (m, 2H), 7.43 – 7.32 (m, 6H), 7.03 (d, *J* = 8.8 Hz, 1H), 5.21 (d, *J* = 18.7 Hz, 4H), 4.00 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 162.1, 155.3, 148.6, 138.6, 135.4, 135.3, 134.4, 133.8, 129.5, 128.9, 128.8, 128.6, 128.5, 128.2, 125.1, 116.0, 111.0, 102.1, 56.3, 55.8, 44.6. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₁N₄O₃, 425.1608; Found: 425.1605.

Methyl-5-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-2-methoxybenzoate (16)



White solid (33.8 mg, 74%); m.p. 119.5 – 120.7 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.50 (d, *J* = 2.3 Hz, 1H), 8.19 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.57 – 7.53 (m, 2H), 7.50 – 7.46 (m, 2H), 7.40 – 7.30 (m, 6H), 7.04 (d, *J* = 8.9 Hz, 1H), 5.21 (d, *J* = 17.6 Hz, 4H), 3.97 (s, 3H), 3.94 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 166.2, 160.3, 155.5, 148.7, 139.8, 135.6, 133.5, 131.9, 129.5, 128.8, 128.6, 128.3, 128.1, 124.2, 120.0, 111.7, 56.2, 55.7, 52.2, 44.5.. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₂₄N₃O₅, 458.1710; Found: 458.1718.


4-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenethyl acetate (17)



White solid (32.7 mg, 72%); m.p. 104.2 – 105.5 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.94 (d, *J* = 8.3 Hz, 2H), 7.59 – 7.53 (m, 2H), 7.51 – 7.45 (m, 2H), 7.41 – 7.29 (m, 8H), 5.23 (s, 2H), 5.19 (s, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 3.00 (t, *J* = 6.9 Hz, 2H), 2.06 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 171.0, 155.5, 148.8, 141.0, 140.1, 135.62, 135.59, 130.4, 129.6, 128.82, 128.80, 128.77, 128.58, 128.56, 128.3, 128.1, 64.6, 55.7, 44.5, 34.9, 21.0. HRMS (ESI-TOF)


m/z: [M + H]⁺ Calcd for C₂₇H₂₆N₃O₄, 456.1918; Found: 456.1923.

1,3-dibenzyl-6-(4'-bromo-[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione (18)




White solid (30.2 mg, 58%); m.p. 144.5 – 145.8 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.09 (d, *J* = 8.4 Hz, 2H), 7.66 – 7.56 (m, 6H), 7.51 (d, *J* = 8.5 Hz, 4H), 7.43 – 7.31 (m, 6H), 5.24 (d, *J* = 17.0 Hz, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 155.5, 148.7, 141.4, 140.7, 139.2, 135.6, 135.5, 132.0, 131.3, 129.6, 128.94, 128.86, 128.8, 128.7, 128.6, 128.4, 128.1, 126.7, 122.1, 55.8, 44.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₉H₂₃BrN₃O₂, 524.0968; Found: 524.0970.

***N*-(4-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenyl)-2,2,2-trifluoroacetamide (19)**




White solid (32.6 mg, 68%); m.p. 166.9 – 167.6 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.13 – 8.07 (m, 2H), 8.02 (s, 1H), 7.66 (d, *J* = 8.8 Hz, 2H), 7.57 – 7.53 (m, 2H), 7.50 – 7.46 (m, 2H), 7.43 – 7.30 (m, 6H), 5.22 (d, *J* = 19.1 Hz, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 155.4, 154.7 (q, *J* = 37.7 Hz), 148.7, 139.9, 136.5, 135.5 (d, *J* = 4.7 Hz), 134.3, 130.2, 130.0, 129.5, 128.8, 128.6, 128.4, 128.2, 127.7, 119.9, 65.4, 55.8, 44.6. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -75.6. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₅H₂₀F₃N₄O₃, 481.1482; Found: 481.1490.

***N*-(3-(4-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-2-methylphenoxy)-3-phenylpropyl)-2,2,2-trifluoro-N-methylacetamide (20)**




White solid (33.8 mg, 53%); m.p. 85.4 – 86.1 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.79 (s, 1H), 7.64 (dd, J = 8.6, 2.2 Hz, 1H), 7.52 (dd, J = 7.7, 1.6 Hz, 2H), 7.45 (dd, J = 7.8, 1.5 Hz, 2H), 7.38 – 7.27 (m, 11H), 6.62 (dd, J = 15.0, 8.7 Hz, 1H), 5.27 (dd, J = 8.4, 4.1 Hz, 1H), 5.19 (s, 2H), 5.16 (s, 2H), 3.80 – 3.55 (m, 2H), 3.18 – 3.03 (m, 3H), 2.41 (d, J = 4.1 Hz, 3H), 2.36 – 2.21 (m, 2H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 157.1, 156.9, 155.6, 148.8, 141.0, 141.0, 140.5, 140.1, 135.7, 130.8, 129.5, 129.0, 128.9, 128.7, 128.5, 128.2, 128.2, 128.0, 127.4, 127.4, 126.8, 126.8, 125.6, 125.4, 124.5, 124.4, 112.2, 112.1, 55.6, 47.1, 46.6, 44.4, 37.5, 35.6, 35.4, 35.4, 34.8, 16.6, 16.5. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -68.93, -69.84. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₆H₃₄F₃N₄O₄, 643.2527; Found: 643.2535.

2-chloro-N-(4'-chloro-5-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-[1,1'-biphenyl]-2-yl)nicotinamide (21)




White solid (45.1 mg, 71%); m.p. 142.1 – 142.8 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.62 (d, J = 8.7 Hz, 1H), 8.49 (dd, J = 4.7, 1.9 Hz, 1H), 8.34 (s, 1H), 8.24 – 8.18 (m, 1H), 8.10 (dd, J = 8.7, 2.0 Hz, 1H), 8.00 (d, J = 2.1 Hz, 1H), 7.56 – 7.52 (m, 2H), 7.50 – 7.47 (m, 4H), 7.42 – 7.31 (m, 9H), 5.24 (s, 2H), 5.19 (s, 2H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 162.4, 155.4, 151.5, 148.7, 146.6, 140.5, 140.0, 136.0, 135.6, 135.52, 135.47, 134.8, 131.4, 130.9, 130.8, 130.2, 129.50, 129.46, 128.9, 128.83, 128.79, 128.63, 128.61, 128.4, 128.1, 123.0, 121.1, 55.8, 44.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₅H₂₆Cl₂N₅O₃, 634.1407; Found: 634.1424.

1,3-dibenzyl-6-(4-(4-(2-(pyridin-2-yloxy)propoxy)phenoxy)phenyl)-1,3,5-triazine-2,4(1*H*,3*H*)-dione (22)




Yellow solid (39.2 mg, 64%); m.p. 62.7 – 64.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.19 (dd, *J* = 5.0, 1.5 Hz, 1H), 8.02 – 7.91 (m, 2H), 7.62 – 7.54 (m, 3H), 7.50 – 7.46 (m, 2H), 7.41 – 7.31 (m, 6H), 7.03 – 6.96 (m, 6H), 6.91 – 6.88 (m, 1H), 6.78 (d, *J* = 8.3 Hz, 1H), 5.67 – 5.60 (m, 1H), 5.21 (d, *J* = 11.6 Hz, 4H), 4.23 (dd, *J* = 9.9, 5.3 Hz, 1H), 4.12 (dd, *J* = 9.9, 4.8 Hz, 1H), 1.52 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 163.1, 160.3, 155.7, 155.6, 149.4, 148.8, 146.8, 140.7, 138.7, 135.7, 130.0, 129.5, 128.82, 128.77, 128.6, 128.3, 128.1, 126.1, 121.3, 116.83, 116.80, 115.9, 111.7, 71.1, 69.2, 55.7, 44.5, 17.0. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₇H₃₃N₄O₅, 613.2445; Found: 613.2454.

Methyl-2-(4'-(2,4-dibenzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-2-fluoro-[1,1'-biphenyl]-4-yl)propanoate (23)



White solid (39.8 mg, 72%); m.p. 61.7 – 62.2 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.09 (d, *J* = 8.5 Hz, 2H), 7.66 – 7.62 (m, 2H), 7.60 – 7.56 (m, 2H), 7.53 – 7.49 (m, 2H), 7.47 – 7.33 (m, 7H), 7.22 – 7.15 (m, 2H), 5.26 (s, 2H), 5.22 (s, 2H), 3.81 (q, *J* = 7.2 Hz, 1H), 3.74 (s, 3H), 1.58 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 174.4, 159.8 (d, *J* = 249.1 Hz), 155.5, 148.8, 142.3 (d, *J* = 7.7 Hz), 140.8, 137.1, 135.62, 135.56, 131.3, 130.7 (d, *J* = 3.7 Hz), 129.6, 128.9, 128.8, 128.6, 128.5, 128.4, 128.1, 127.1, 127.0, 123.7 (d, *J* = 3.3 Hz), 115.4 (d, *J* = 23.5 Hz), 55.8, 52.3, 45.0, 44.5, 18.4. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -117.03. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₃H₂₉FN₃O₄, 550.2137; Found: 550.2149.


3-ethyl-1-propyl-6-(*p*-tolyl)-1,3,5-triazine-2,4(1*H*,3*H*)-dione (24)



White solid (20.0 mg, 73%); m.p. 96.5 – 97.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.96 –


7.84 (m, 2H), 7.26 (d, $J = 8.0$ Hz, 2H), 4.14 (q, $J = 7.2$ Hz, 2H), 4.04 – 3.97 (m, 2H), 2.42 (s, 3H), 1.70 – 1.79 (m, 2H), 1.42 (t, $J = 7.2$ Hz, 3H), 1.01 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.7, 148.5, 140.9, 140.0, 129.5, 129.0, 128.2, 47.1, 42.7, 21.4, 20.6, 13.5, 11.4. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₅H₂₀N₃O₂, 274.1550; Found: 274.1559.

2,4-di(prop-2-yn-1-yl)-6-(*p*-tolyl)-1,2,4-triazine-3,5(2*H*,4*H*)-dione (25)




White solid (19.8 mg, 71%); m.p. 149.0 – 149.7 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.95 (d, $J = 8.0$ Hz, 2H), 7.27 (d, $J = 8.4$ Hz, 2H), 4.84 (dd, $J = 30.2, 1.8$ Hz, 4H), 2.42 (s, 4H), 2.27 (s, 1H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.6, 147.5, 141.7, 140.8, 129.1, 128.6, 128.4, 76.8, 76.7, 73.7, 71.7, 41.7, 30.3, 21.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₄N₃O₂, 280.1081; Found: 280.1079.

2,4-diallyl-6-(*p*-tolyl)-1,2,4-triazine-3,5(2*H*,4*H*)-dione (26)



White solid (16.1 mg, 57%); m.p. 92.0 – 92.7 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.91 (d, $J = 8.2$ Hz, 2H), 7.26 (d, $J = 8.1$ Hz, 2H), 6.08 – 5.89 (m, 2H), 5.41 – 5.26 (m, 4H), 4.67 (dd, $J = 16.3, 6.1$ Hz, 4H), 2.42 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.3, 148.3, 141.2, 140.3, 131.5, 130.5, 129.2, 129.0, 128.3, 119.3, 119.2, 54.4, 43.2, 21.4. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₈N₃O₂, 284.1394; Found: 284.1400.


2-(4-chlorophenyl)-2-(2,6-dichloro-4-(4-methyl-3,5-dioxo-6-(*p*-tolyl)-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)phenyl)acetonitrile (27)



White solid (27.0 mg, 53%); m.p. 123.0 – 123.6 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.94


(d, $J = 8.3$ Hz, 2H), 7.87 (s, 2H), 7.40 – 7.29 (m, 6H), 6.22 (s, 1H), 3.53 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 155.0, 148.0, 142.7, 141.7, 141.3, 135.7, 134.3, 130.8, 129.9, 129.3, 129.2, 128.6, 128.4, 128.2, 125.0, 116.3, 37.0, 27.9, 21.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₅H₁₈C₁₃N₄O₂, 511.0490; Found: 511.0501.

(2*R*,3*R*,4*R*,5*R*)-2-(acetoxymethyl)-5-(3,5-dioxo-6-(*p*-tolyl)-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)tetrahydrofuran-3,4-diyl diacetate (28)



White solid (23.5 mg, 51%); m.p. 107.0 – 107.5 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 9.62 (s, 1H), 7.95 (d, $J = 8.2$ Hz, 2H), 7.28 (d, $J = 8.1$ Hz, 2H), 6.42 (d, $J = 2.8$ Hz, 1H), 5.78 (dd, $J = 5.3, 2.9$ Hz, 1H), 5.67 – 5.59 (m, 1H), 4.39 (ddt, $J = 10.6, 7.2, 3.2$ Hz, 2H), 4.23 – 4.14 (m, 1H), 2.41 (s, 3H), 2.15 (d, $J = 7.3$ Hz, 6H), 1.84 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 170.6, 169.7, 169.6, 155.3, 148.0, 143.4, 141.3, 129.3, 128.4, 128.1, 88.1, 79.1, 73.1, 70.3, 62.8, 21.4, 20.54, 20.50, 20.4. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₂₁H₂₃N₃NaO₉, 484.1327; Found: 484.1333.


(2*R*,3*R*,4*R*,5*R*)-4-acetoxy-2-((benzoyloxy)methyl)-5-(3,5-dioxo-6-(*p*-tolyl)-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)tetrahydrofuran-3-yl benzoate (29)



White solid (30.4 mg, 52%); m.p. 129.5 – 130.2 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 9.41 (s, 1H), 8.01 – 7.93 (m, 4H), 7.74 (d, $J = 8.2$ Hz, 2H), 7.58 – 7.52 (m, 2H), 7.39 (t, $J = 7.8$ Hz, 2H), 7.31 (d, $J = 7.8$ Hz, 2H), 6.91 (d, $J = 8.1$ Hz, 2H), 6.35 (d, $J = 3.6$ Hz, 1H), 5.90 (dd, $J = 3.6, 2.1$ Hz, 1H), 5.76 (dd, $J = 4.6, 2.0$ Hz, 1H), 4.81 (dt, $J = 6.6, 4.8$ Hz, 1H), 4.70 (h, $J = 6.8$ Hz, 2H), 2.30 (s, 3H), 2.20 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 169.9, 166.1, 165.6, 155.3, 148.2, 143.4, 140.7, 133.5, 133.2, 130.0, 129.7, 129.4, 128.9, 128.7, 128.5, 128.4, 128.0, 89.7, 78.8, 76.3, 62.3, 21.4, 20.7. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₃₁H₂₇N₃NaO₉, 608.1640; Found: 608.1647.


(2*R*,3*R*,4*R*,5*R*)-5-((benzoyloxy)methyl)-2-(3,5-dioxo-6-(*p*-tolyl)-4,5-dihydro-1,2,4-

triazin-2(3H)-yl)-3-methyltetrahydrofuran-3,4-diyI dibenzoate (30)




White solid (31.1 mg, 47%); m.p. 131.3 – 132.9 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 9.19 (s, 1H), 8.21 – 8.11 (m, 4H), 8.05 (d, J = 8.3 Hz, 2H), 7.97 – 7.89 (m, 2H), 7.64 (t, J = 7.4 Hz, 2H), 7.55 – 7.45 (m, 5H), 7.34 (d, J = 8.1 Hz, 2H), 7.28 – 7.22 (m, 3H), 6.25 (d, J = 8.8 Hz, 1H), 4.83 (ddd, J = 8.7, 7.1, 4.1 Hz, 1H), 4.72 (dd, J = 11.8, 4.1 Hz, 1H), 4.60 (dd, J = 11.8, 7.1 Hz, 1H), 2.45 (s, 3H), 1.89 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 166.1, 165.6, 164.9, 155.1, 147.9, 143.4, 141.4, 133.7, 133.5, 133.0, 130.2, 130.0, 129.9, 129.7, 129.6, 129.4, 129.0, 128.60, 128.56, 128.4, 128.2, 128.0, 88.4, 87.3, 65.0, 21.5, 17.6. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₃₇H₃₁N₃NaO₉, 684.1953; Found: 684.1962.

*(2*R*,3*R*,4*R*,5*R*)-2-((benzoyloxy)methyl)-5-(3,5-dioxo-6-(*p*-tolyl)-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)tetrahydrofuran-3,4-diyI dibenzoate (31)*




White solid (45.9 mg, 71%); m.p. 127.6 – 128.7 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 9.35 (s, 1H), 7.98 (dd, J = 12.0, 8.2 Hz, 8H), 7.58 (td, J = 7.4, 3.4 Hz, 2H), 7.44 (dq, J = 22.0, 7.4 Hz, 5H), 7.24 (dd, J = 8.2, 2.1 Hz, 3H), 6.68 (d, J = 2.9 Hz, 1H), 6.24 (dd, J = 5.4, 3.0 Hz, 1H), 6.06 (t, J = 6.1 Hz, 1H), 4.91 – 4.72 (m, 2H), 4.60 (dd, J = 12.1, 4.9 Hz, 1H), 2.42 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 166.2, 165.3, 165.2, 155.3, 147.9, 143.4, 141.2, 133.7, 133.6, 133.1, 129.9, 129.8, 129.7, 129.4, 129.3, 128.8, 128.7, 128.53, 128.50, 128.48, 128.3, 128.0, 88.6, 73.7, 71.3, 63.6, 21.5. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₃₆H₂₉N₃NaO₉, 670.1796; Found: 670.1791.

*((2*R*,3*R*,4*R*,5*R*)-3-(benzoyloxy)-5-(3,5-dioxo-6-(*p*-tolyl)-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)-4-fluorotetrahydrofuran-2-yl)methyl benzoate (32)*




White solid (33.8 mg, 62%); m.p. 101.3 – 102.7 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 9.46 (s, 1H), 8.10 (d, J = 8.0 Hz, 2H), 7.96 (t, J = 7.4 Hz, 4H), 7.64 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 6.8 Hz, 3H), 7.43 – 7.12 (m, 5H), 6.82 (d, J = 6.4 Hz, 1H), 6.31 (dt, J = 16.2, 6.4 Hz, 1H), 5.66 (dt, J = 51.5, 6.1 Hz, 1H), 4.76 (dd, J = 11.6, 4.1 Hz, 1H), 4.70 – 4.62 (m, 1H), 4.53 (q, J = 6.5 Hz, 1H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 166.0, 165.5, 155.2, 148.3, 143.5, 141.2, 133.8, 133.1, 129.9, 129.7, 129.4, 128.7, 128.6, 128.5, 128.3, 128.0, 92.5 (d, J = 203.1 Hz), 82.9 (d, J = 16.9 Hz), 78.5 (d, J = 8.7 Hz), 75.7 (d, J = 22.8 Hz), 65.1, 21.5. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -202.82. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₂₉H₂₄FN₃NaO₇, 568.1490; Found: 568.1495.

(2*R*,3*R*,4*R*,5*R*)-2-(acetoxymethyl)-5-(4-benzyl-3,5-dioxo-6-(*p*-tolyl)-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)tetrahydrofuran-3,4-diyl diacetate (33)




White solid (32.5 mg, 59%); m.p. 142.5 – 143.2 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.92 (d, J = 8.3 Hz, 2H), 7.59 – 7.53 (m, 2H), 7.36 – 7.26 (m, 5H), 6.46 (d, J = 2.9 Hz, 1H), 5.78 (dd, J = 5.3, 2.9 Hz, 1H), 5.69 – 5.58 (m, 1H), 5.25 – 5.13 (m, 2H), 4.41 – 4.32 (m, 2H), 4.22 – 4.15 (m, 1H), 2.41 (s, 3H), 2.15 (s, 3H), 2.13 (s, 3H), 1.82 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 170.6, 169.6, 169.5, 155.0, 148.6, 142.7, 141.0, 135.2, 129.8, 129.2, 128.7, 128.6, 128.5, 128.2, 88.9, 79.0, 79.0, 73.1, 70.2, 62.8, 44.6, 21.4, 20.6, 20.5, 20.4. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₂₈H₂₉N₃NaO₉, 574.1796; Found: 574.1805.

2-((2*R*,3*R*,4*R*,5*R*)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-yl)-4-methyl-6-(*p*-tolyl)-1,2,4-triazine-3,5(2*H*,4*H*)-dione (34)




White solid (41.4 mg, 67%); m.p. 112.9 – 114.1 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.73 (d, *J* = 8.2 Hz, 2H), 7.35 – 7.30 (m, 7H), 7.29 – 7.25 (m, 6H), 7.23 (dt, *J* = 6.0, 3.3 Hz, 2H), 7.19 (d, *J* = 8.1 Hz, 2H), 6.49 (d, *J* = 3.6 Hz, 1H), 4.67 (dd, *J* = 12.1, 4.2 Hz, 2H), 4.60 (dd, *J* = 12.1, 4.1 Hz, 2H), 4.55 – 4.45 (m, 2H), 4.39 (dt, *J* = 7.5, 3.8 Hz, 2H), 4.31 (t, *J* = 5.5 Hz, 1H), 3.63 (qd, *J* = 10.8, 4.5 Hz, 2H), 3.40 (s, 3H), 2.43 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 155.3, 148.7, 141.4, 140.3, 137.9, 137.6, 137.4, 129.1, 129.0, 128.43, 128.40, 128.36, 128.3, 128.1, 128.0, 127.96, 127.93, 127.6, 89.5, 81.4, 78.6, 76.6, 73.4, 72.5, 72.4, 69.7, 27.5, 21.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₇H₃₈N₃O₆, 620.2755; Found: 620.2753.

*N-(5-((2*R*,3*R*,4*R*,5*R*)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-yl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-4'-chloro-[1,1'-biphenyl]-2-yl)-2-chloronicotinamide (35)*




White solid (37.4 mg, 43%); m.p. 62.0 – 63.1 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.57 (d, *J* = 8.7 Hz, 1H), 8.49 (dd, *J* = 4.7, 1.9 Hz, 1H), 8.34 (s, 1H), 8.22 (d, *J* = 7.4 Hz, 1H), 7.93 (d, *J* = 2.0 Hz, 1H), 7.87 (dd, *J* = 8.8, 1.9 Hz, 1H), 7.46 – 7.40 (m, 3H), 7.36 – 7.27 (m, 14H), 7.19 (dd, *J* = 6.7, 2.4 Hz, 2H), 6.49 (d, *J* = 3.8 Hz, 1H), 4.72 – 4.53 (m, 5H), 4.44 – 4.37 (m, 4H), 4.30 (t, *J* = 5.3 Hz, 1H), 3.65 – 3.56 (m, 2H), 3.40 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 162.4, 155.2, 151.6, 148.6, 146.6, 140.4, 140.1, 137.8, 137.5, 137.4, 136.1, 135.6, 134.9, 131.3, 130.8, 130.4, 129.5, 128.8, 128.6, 128.5, 128.44, 128.4, 128.3, 128.02, 127.98, 127.96, 127.6, 127.5, 123.0, 121.2, 89.6, 81.5, 78.6, 73.3, 72.6, 72.5, 69.6, 27.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₄₈H₄₂Cl₂N₅O₇, 870.2456; Found: 870.2460.

*Methyl-2-(4'-(2-((2*R*,3*R*,4*R*,5*R*)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-yl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-2-fluoro-[1,1'-biphenyl]-4-yl)propanoate (36)*



White solid (49.5 mg, 63%); m.p. 108.7 – 109.4 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.90 (d, *J* = 8.6 Hz, 2H), 7.61 – 7.54 (m, 2H), 7.46 (s, 1H), 7.36 – 7.23 (m, 16H), 6.52 (d, *J* = 3.7 Hz, 1H), 4.76 – 4.58 (m, 5H), 4.53 (dd, *J* = 12.4, 8.1 Hz, 2H), 4.44 – 4.33 (m, 3H), 3.83 (q, *J* = 7.2, 6.2 Hz, 1H), 3.75 (s, 3H), 3.70 – 3.62 (m, 2H), 3.43 (s, 3H), 1.60 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 174.4, 159.8 (d, *J* = 249.2 Hz), 155.6, 155.3, 148.7, 142.5 (d, *J* = 7.7 Hz), 140.9, 138.1, 137.9, 137.7, 137.6, 137.4, 137.3, 137.2, 134.4, 131.1, 130.7 (d, *J* = 3.6 Hz), 128.8 (d, *J* = 3.2 Hz), 128.5, 128.5, 128.4, 128.3, 128.1, 128.0, 128.0, 127.6, 127.6, 127.5, 127.0 (d, *J* = 13.3 Hz), 125.6, 123.8 (d, *J* = 3.3 Hz), 115.5 (d, *J* = 23.5 Hz), 89.5, 81.5, 78.5, 76.4, 73.4, 72.5, 72.4, 69.6, 52.3, 45.0, 31.3, 27.6, 18.5. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -117.02. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₄₆H₄₅FN₃O₈, 786.3185; Found: 786.3187.


(2*R*,3*R*,4*R*,5*R*)-2-(acetoxymethyl)-5-(4-benzyl-6-(4'-chloro-6-(2-chloronicotinamido)-[1,1'-biphenyl]-3-yl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)tetrahydrofuran-3,4-diyil diacetate compound with methane (37)



White solid (33.5 mg, 41%); m.p. 100.0 – 101.1 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.66 (d, *J* = 8.7 Hz, 1H), 8.48 (dd, *J* = 4.7, 2.0 Hz, 1H), 8.37 (s, 1H), 8.23 – 8.18 (m, 1H), 8.13 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.99 (d, *J* = 2.1 Hz, 1H), 7.57 – 7.53 (m, 2H), 7.50 – 7.46 (m, 2H), 7.42 – 7.31 (m, 6H), 6.44 (d, *J* = 2.9 Hz, 1H), 5.78 (dd, *J* = 5.4, 2.9 Hz, 1H), 5.60 – 5.54 (m, 1H), 5.18 (d, *J* = 2.7 Hz, 2H), 4.42 – 4.32 (m, 2H), 4.20 – 4.14 (m, 1H), 2.14 (s, 3H), 2.12 (s, 3H), 1.86 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.4, 169.4, 169.4, 154.9, 151.5, 148.5, 146.6, 141.6, 140.4, 136.6, 135.4, 135.1, 134.9, 131.6, 131.0, 130.8, 130.5, 129.7, 129.5, 129.2, 128.6, 128.3, 128.0, 123.0, 121.2, 89.2, 73.0, 70.3, 62.9, 44.7, 20.5, 20.4, 20.4. HRMS (ESI-TOF) *m/z*:


$[M + Na]^+$ Calcd for $C_{40}H_{37}Cl_2N_5NaO_{10}$, 840.1810; Found: 840.1815.

(2*R*,3*R*,4*R*,5*R*)-2-(acetoxymethyl)-5-(4-benzyl-6-(2'-fluoro-4'-(1-methoxy-1-oxopropan-2-yl)-[1,1'-biphenyl]-4-yl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3*H*)-yl)tetrahydrofuran-3,4-diyI diacetate (38)



White solid (33.7 mg, 47%); m.p. 97.0 – 98.1 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.10 (d, $J = 8.5$ Hz, 2H), 7.70 – 7.62 (m, 2H), 7.62 – 7.55 (m, 2H), 7.44 (t, $J = 8.0$ Hz, 1H), 7.38 – 7.32 (m, 3H), 7.22 – 7.13 (m, 2H), 6.47 (d, $J = 3.0$ Hz, 1H), 5.81 (dd, $J = 5.3, 3.0$ Hz, 1H), 5.65 – 5.60 (m, 1H), 5.29 – 5.15 (m, 2H), 4.44 – 4.35 (m, 2H), 4.21 (dd, $J = 12.0, 4.6$ Hz, 1H), 3.79 (q, $J = 7.2$ Hz, 1H), 3.73 (s, 3H), 2.16 (s, 3H), 2.13 (s, 3H), 1.82 (s, 3H), 1.56 (d, $J = 7.2$ Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 174.3, 170.6, 169.6, 169.5, 161.0, 155.0, 148.6, 142.3, 137.8, 135.1, 130.69, 130.67, 130.7, 129.8, 129.6, 129.0 (d, $J = 3.1$ Hz), 128.7 (d, $J = 4.9$ Hz), 128.3, 127.0, 126.8, 123.7 (d, $J = 3.1$ Hz), 115.4 (d, $J = 23.5$ Hz), 89.0, 79.1, 73.0, 70.3, 62.8, 52.3, 45.0, 44.7, 20.5 (d, $J = 5.3$ Hz), 20.3, 18.4. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -116.94. HRMS (ESI-TOF) m/z : [M + H] $^+$ Calcd for $C_{37}H_{37}FN_3O_{11}$, 718.2407; Found: 718.2412.


2-((2*R*,3*R*,4*R*,5*R*)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-yl)-4-methyl-6-(4-(4-(2-(pyridin-2-yl)oxy)propoxy)phenoxy)phenyl)-1,2,4-triazine-3,5(2*H*,4*H*)-dione (39)



Colorless oil (38.2 mg, 45%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.19 (dd, $J = 4.9, 1.6$ Hz,


1H), 7.77 (d, J = 8.9 Hz, 2H), 7.60 (td, J = 8.1, 7.4, 1.9 Hz, 1H), 7.34 – 7.22 (m, 14H), 7.07 – 6.99 (m, 4H), 6.94 – 6.84 (m, 3H), 6.81 – 6.75 (m, 1H), 6.50 (d, J = 3.5 Hz, 1H), 5.65 (h, J = 6.1 Hz, 1H), 4.74 – 4.54 (m, 5H), 4.52 – 4.45 (m, 2H), 4.40 (d, J = 5.1 Hz, 2H), 4.34 – 4.30 (m, 1H), 4.26 (dd, J = 9.9, 5.3 Hz, 1H), 4.14 (dd, J = 9.9, 4.8 Hz, 1H), 3.69 – 3.58 (m, 2H), 3.40 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 163.2, 160.4, 155.8, 155.3, 149.2, 148.7, 146.8, 140.7, 138.7, 137.9, 137.6, 137.4, 130.0, 128.43, 128.40, 128.3, 128.03, 127.99, 128.0, 127.9, 127.6, 127.5, 125.8, 121.4, 116.8, 116.7, 116.0, 111.7, 89.5, 81.4, 76.5, 73.4, 72.5, 72.3, 71.1, 69.7, 69.2, 27.5, 17.0. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₅₀H₄₉N₄O₉, 849.3494; Found: 849.3494.

2-chloro-N-(4'-chloro-5-(2-(3,5-dichloro-4-((4-chlorophenyl)(cyano)methyl)phenyl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-[1,1'-biphenyl]-2-yl)nicotinamide (40)



White solid (26.6 mg, 35%); m.p. 147.3 – 148.6 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.69 (d, J = 8.7 Hz, 1H), 8.50 (dd, J = 4.7, 2.0 Hz, 1H), 8.41 (s, 1H), 8.23 (dd, J = 7.7, 1.7 Hz, 1H), 8.16 (dd, J = 8.8, 2.1 Hz, 1H), 8.00 (d, J = 2.1 Hz, 1H), 7.84 (s, 2H), 7.52 – 7.48 (m, 2H), 7.43 – 7.33 (m, 7H), 6.22 (s, 1H), 3.54 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 162.4, 155.0, 151.6, 147.8, 146.6, 141.6, 141.5, 140.6, 136.9, 135.8, 135.3, 135.1, 134.4, 131.6, 130.9, 130.7, 130.6, 130.5, 130.2, 129.6, 129.3, 129.2, 128.3, 127.6, 125.2, 123.0, 121.1, 116.2, 37.0, 28.0. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₆H₂₂Cl₅N₆O₃, 761.0191; Found: 761.0186.


1-methyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (41)^[4]



Yellow solid (21.5 mg, 86%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.24 (d, J = 8.2 Hz, 2H), 7.96 – 7.90 (m, 1H), 7.59 – 7.51 (m, 1H), 7.38 – 7.26 (m, 4H), 3.76 (s, 3H), 2.42 (s, 3H); ^{13}C


NMR (101 MHz, Chloroform-*d*) δ 154.8, 154.0, 140.6, 133.4, 133.3, 133.2, 130.3, 130.0, 129.5, 128.8, 123.7, 113.5, 29.3, 21.5.

1-ethyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (42)




Light yellow solid (22.5 mg, 85%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.25 (d, *J* = 8.2 Hz, 2H), 7.95 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.55 (td, *J* = 7.8, 7.2, 1.4 Hz, 1H), 7.38 – 7.32 (m, 2H), 7.29 (d, *J* = 8.2 Hz, 2H), 4.39 (q, *J* = 7.2 Hz, 2H), 2.42 (s, 3H), 1.42 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.3, 154.0, 140.6, 133.5, 133.3, 132.2, 130.6, 130.0, 129.6, 128.8, 123.5, 113.4, 37.6, 21.5, 12.4.

1,6,7-trimethyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (43)^[5]




Yellow solid (21.7 mg, 78%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.22 (d, *J* = 8.1 Hz, 2H), 7.65 (s, 1H), 7.26 (d, *J* = 8.2 Hz, 2H), 7.05 (s, 1H), 3.70 (s, 3H), 2.40 (s, 6H), 2.34 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.8, 152.7, 140.2, 139.9, 133.6, 132.5, 131.6, 131.3, 130.4, 129.4, 128.7, 114.1, 29.1, 21.5, 20.6, 19.2.

1-allyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (44)




Yellow solid (20.5 mg, 74%); m.p. 107.3 – 108.05 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.27 (d, *J* = 8.2 Hz, 2H), 7.98 – 7.91 (m, 1H), 7.57 – 7.47 (m, 1H), 7.32 (dt, *J* = 20.5, 7.7 Hz, 4H), 5.98 (m, *J* = 15.6, 10.3, 5.1 Hz, 1H), 5.25 (dd, *J* = 27.0, 13.9 Hz, 2H), 4.97 (d, *J* = 5.1 Hz, 2H), 2.42 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.3, 154.0, 140.7, 133.3, 133.2, 132.5, 130.7, 130.4, 129.9, 129.6, 128.8, 123.6, 118.1, 114.0, 44.7, 21.5. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₁₈H₁₆N₂NaO, 299.1155; Found: 299.1157

1-(prop-2-yn-1-yl)-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (45)




Light yellow solid (19.2 mg, 70%); m.p. 170.4 – 171.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.25 (d, *J* = 8.3 Hz, 2H), 7.94 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.58 (m, *J* = 8.6, 7.3, 1.5 Hz, 1H), 7.49 – 7.45 (m, 1H), 7.41 – 7.36 (m, 1H), 7.28 (d, *J* = 8.1 Hz, 2H), 5.11 (d, *J* = 2.5 Hz, 2H), 2.42 (s, 3H), 2.30 (t, *J* = 2.5 Hz, 1H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 153.83, 153.78, 140.9, 133.3, 133.0, 131.8, 130.5, 130.2, 129.6, 128.9, 124.1, 114.0, 73.1, 31.7, 21.6. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₁₈H₁₄N₂NaO, 297.0998; Found: 297.1003.

1-(2-hydroxyethyl)-3-(p-tolyl)quinoxalin-2(1H)-one (46)




Yellow solid (18.3 mg, 65%); m.p. 163.4 – 164.4 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.23 (d, *J* = 8.2 Hz, 2H), 7.97 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.59 – 7.53 (m, 1H), 7.44 (d, *J* = 8.3 Hz, 1H), 7.39 (t, *J* = 7.9 Hz, 1H), 7.31 (d, *J* = 8.1 Hz, 2H), 4.57 (t, *J* = 5.5 Hz, 2H), 4.10 (t, *J* = 5.5 Hz, 2H), 2.44 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 155.8, 153.8, 140.8, 133.5, 133.0, 132.7, 130.6, 130.1, 129.5, 128.9, 123.9, 113.7, 60.8, 45.2, 21.5. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₁₇H₁₆N₂NaO₂, 303.1104; Found: 303.1106.

methyl 2-(2-oxo-3-(p-tolyl)quinoxalin-1(2H)-yl)acetate (47)




Yellow solid (16.5 mg, 54%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.29 (d, *J* = 8.3 Hz, 2H), 7.99 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.55 (ddd, *J* = 8.5, 7.4, 1.5 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.31 (d, *J* = 8.1 Hz, 2H), 7.14 – 7.10 (m, 1H), 5.13 (s, 2H), 3.82 (s, 3H), 2.45 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 167.8, 154.3, 153.7, 140.9, 133.2, 133.0, 132.4, 130.7, 130.2, 129.6, 128.8, 124.0, 112.9, 52.9, 43.6, 21.5.

ethyl 2-(2-oxo-3-(p-tolyl)quinoxalin-1(2H)-yl)acetate (48)^[5]




Yellow solid (22.3 mg, 69%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.29 (d, $J = 8.2$ Hz, 2H), 7.97 (d, $J = 8.0$ Hz, 1H), 7.56 – 7.50 (m, 1H), 7.38 (t, $J = 7.6$ Hz, 1H), 7.31 (d, $J = 8.1$ Hz, 2H), 7.11 (d, $J = 8.3$ Hz, 1H), 5.10 (s, 2H), 4.29 (q, $J = 7.1$ Hz, 2H), 2.44 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 167.3, 154.4, 153.7, 140.8, 133.2, 133.0, 132.5, 130.7, 130.2, 129.6, 128.8, 124.0, 113.0, 62.1, 43.8, 21.5, 14.1.

tert-butyl 2-(2-oxo-3-(p-tolyl)quinoxalin-1(2H)-yl)acetate (49)




Yellow solid (24.5 mg, 70%); m.p. 123.9 – 125.0 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.25 (d, $J = 8.2$ Hz, 2H), 7.95 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.55 – 7.49 (m, 1H), 7.38 – 7.33 (m, 1H), 7.28 (d, $J = 8.1$ Hz, 2H), 7.09 (d, $J = 8.3$ Hz, 1H), 5.00 (s, 2H), 2.42 (s, 3H), 1.47 (s, 9H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 166.3, 154.4, 153.8, 140.8, 133.2, 133.1, 132.5, 130.6, 130.1, 129.6, 128.8, 123.9, 113.0, 83.1, 44.4, 28.0, 21.5. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₂₁H₂₂N₂NaO₃, 373.1523; Found: 373.1527.

1-benzyl-3-(p-tolyl)quinoxalin-2(1H)-one (50)^[5]




Light yellow solid (25.8 mg, 79%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.33 (d, $J = 8.2$ Hz, 2H), 7.97 (dd, $J = 8.0, 1.4$ Hz, 1H), 7.46 (m, $J = 8.5, 8.0, 1.5$ Hz, 1H), 7.32 (m, $J = 9.3, 4.5$ Hz, 9H), 5.60 (s, 2H), 2.46 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.9, 154.1, 140.8, 135.4, 133.4, 133.3, 132.6, 130.5, 130.0, 129.6, 128.93, 128.86, 127.7, 127.0, 123.7, 114.3, 46.1, 21.6.

1-(4-methylbenzyl)-3-(p-tolyl)quinoxalin-2(1H)-one (51)




Light yellow solid (27.8 mg, 82%); m.p. 162.8 – 163.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.29 (d, *J* = 8.2 Hz, 2H), 7.92 (d, *J* = 8.1 Hz, 1H), 7.44 – 7.38 (m, 1H), 7.33 – 7.27 (m, 4H), 7.19 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 5.52 (s, 2H), 2.42 (s, 3H), 2.30 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.9, 154.1, 140.7, 137.4, 133.4, 133.3, 132.7, 132.4, 130.4, 130.0, 129.63, 129.58, 128.9, 127.0, 123.7, 114.3, 45.9, 21.6, 21.1. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₂₃H₂₀N₂NaO, 363.1468; Found: 363.1473.

1-(4-bromobenzyl)-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (52)




Yellow solid (25.5 mg, 63%); m.p. 149.7 – 150.2 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.29 (d, *J* = 8.1 Hz, 2H), 7.95 (d, *J* = 7.8 Hz, 1H), 7.47 – 7.41 (m, 3H), 7.32 (dd, *J* = 16.1, 8.0 Hz, 3H), 7.19 (m, *J* = 13.1, 8.4 Hz, 3H), 5.50 (s, 2H), 2.43 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.8, 154.0, 140.9, 134.5, 133.4, 133.1, 132.4, 132.1, 130.6, 130.1, 129.6, 128.9, 128.8, 123.9, 121.6, 114.0, 45.6, 21.6. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₂₂H₁₇BrN₂NaO, 427.0416; Found: 427.0423.

6-chloro-1-methyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (53)^[5]




Yellow solid (19.4 mg, 68%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.25 (d, *J* = 8.3 Hz, 2H), 7.91 (d, *J* = 2.3 Hz, 1H), 7.49 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.29 (d, *J* = 8.2 Hz, 2H), 7.24 (d, *J* = 8.9 Hz, 1H), 3.74 (s, 3H), 2.42 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 155.0, 154.4, 141.1, 133.6, 132.9, 132.0, 129.9, 129.6, 129.5, 128.93, 128.87, 114.6, 29.5, 21.6.

7-fluoro-1-methyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (54)^[5]




Light yellow solid (19.3 mg, 72%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.20 (d, J = 8.1 Hz, 2H), 7.88 (dd, J = 8.8, 6.0 Hz, 1H), 7.27 (d, J = 8.1 Hz, 2H), 7.05 (td, J = 8.5, 2.5 Hz, 1H), 6.98 (dd, J = 10.0, 2.4 Hz, 1H), 3.69 (s, 3H), 2.41 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 164.5, 162.0, 154.6, 152.8 (d, J = 3.7 Hz), 140.7, 134.7 (d, J = 11.4 Hz), 133.1, 132.2 (d, J = 10.3 Hz), 129.9 (d, J = 1.7 Hz), 129.4, 128.8, 111.5 (d, J = 23.5 Hz), 100.5 (d, J = 27.9 Hz), 29.5, 21.5. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -107.45.

6-fluoro-1-methyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (55) [5]




Light yellow solid (19.8 mg, 74%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.23 (d, J = 8.2 Hz, 2H), 7.91 (dd, J = 8.8, 6.0 Hz, 1H), 7.30 (d, J = 8.1 Hz, 2H), 7.09 (td, J = 8.5, 2.5 Hz, 1H), 7.02 (dd, J = 10.0, 2.5 Hz, 1H), 3.73 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 164.5, 162.0, 154.6, 152.8 (d, J = 3.6 Hz), 140.7, 134.7 (d, J = 11.3 Hz), 133.1, 132.2 (d, J = 10.5 Hz), 129.9 (d, J = 2.0 Hz), 129.4, 128.8, 111.5 (d, J = 23.6 Hz), 100.5 (d, J = 27.8 Hz), 29.5, 21.5. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -107.45.

6,7-difluoro-1-methyl-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (56)




Yellow solid (20.6 mg, 72%); m.p. 161.3 – 162.6 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.24 (d, J = 8.3 Hz, 2H), 7.71 (dd, J = 10.3, 8.3 Hz, 1H), 7.29 (d, J = 8.1 Hz, 2H), 7.10 (dd, J = 11.4, 7.1 Hz, 1H), 3.69 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.3, 154.0 (d, J = 3.7 Hz), 152.6 (d, J = 14.6 Hz), 150.1 (d, J = 14.5 Hz), 148.0 (d, J = 14.0 Hz), 145.5 (d, J = 14.0 Hz), 141.1, 132.7, 130.4 (dd, J = 8.9, 1.8 Hz), 129.5, 129.3 (dd, J = 9.6, 2.8 Hz), 128.8, 117.6 (dd, J = 17.9, 2.2 Hz), 102.1 (d, J = 23.1 Hz), 29.7, 21.5. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -131.04 (d, J = 22.3 Hz), -142.19 (d, J = 22.4 Hz). HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₁₆H₁₂F₂N₂NaO, 309.0810; Found: 309.0811.

ethyl 2-(7-fluoro-2-oxo-3-(*p*-tolyl)quinoxalin-1(2*H*)-yl)acetate (57)




White solid (19.7 mg, 58%); m.p. 175.9 – 176.6 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.29 (d, J = 8.3 Hz, 2H), 7.67 (dd, J = 8.7, 2.9 Hz, 1H), 7.33 – 7.25 (m, 4H), 7.07 (dd, J = 9.2, 4.6 Hz, 1H), 5.09 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 2.45 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 167.1, 158.9 (d, J = 243.9 Hz), 154.9, 154.0, 141.3, 133.8 (d, J = 11.4 Hz), 132.7, 129.7, 129.1 (d, J = 2.1 Hz), 128.9, 117.8 (d, J = 24.2 Hz), 115.9 (d, J = 22.4 Hz), 114.1 (d, J = 8.9 Hz), 62.2, 44.0, 21.5, 14.1. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -118.70. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₁₈FN₂O₃, 341.1269; Found: 341.1269.

*3-(*p*-tolyl)quinoxalin-2(1*H*)-one (58)^[5]*




Light yellow solid (8.03 mg, 34%); ^1H NMR (400 MHz, DMSO-*d*₆) δ 12.53 (s, 1H), 8.27 (d, J = 8.1 Hz, 2H), 7.82 (d, J = 7.8 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.36 – 7.26 (m, 4H), 2.38 (s, 3H). ^{13}C NMR (101 MHz, DMSO-*d*₆) δ 155.1, 154.2, 140.5, 133.4, 132.5, 132.4, 130.5, 129.6, 129.1, 128.9, 123.8, 115.5, 21.5.

*1-methyl-3-phenylquinoxalin-2(1*H*)-one (59)^[4]*



White solid (18.2 mg, 77%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.33 (dd, J = 6.4, 3.0 Hz, 2H), 7.97 (d, J = 8.0 Hz, 1H), 7.62 – 7.56 (m, 1H), 7.53 – 7.49 (m, 3H), 7.42 – 7.34 (m, 2H), 3.79 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.7, 154.2, 136.1, 133.4, 133.1, 130.5, 130.3, 129.5, 128.1, 123.7, 113.6, 29.3.


*3-(4-ethylphenyl)-1-methylquinoxalin-2(1*H*)-one (60)^[5]*



Yellow solid (22.9 mg, 87%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.31 – 8.25 (m, 2H), 7.96


(dd, $J = 8.0, 1.4$ Hz, 1H), 7.58 (ddd, $J = 8.5, 7.4, 1.5$ Hz, 1H), 7.41 – 7.32 (m, 4H), 3.79 (s, 3H), 2.74 (q, $J = 7.6$ Hz, 2H), 1.30 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.8, 154.1, 146.9, 133.6, 133.3, 133.2, 130.3, 130.0, 129.6, 127.7, 123.7, 113.5, 29.3, 28.9, 15.5.

*3-(4-cyclopropylphenyl)-1-methylquinoxalin-2(1*H*)-one (61)*




Yellow solid (22.9 mg, 83%); m.p. 112.9 – 113.6 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.27 (d, $J = 8.4$ Hz, 2H), 7.95 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.60 – 7.55 (m, 1H), 7.41 – 7.33 (m, 2H), 7.19 (d, $J = 8.4$ Hz, 2H), 3.79 (s, 3H), 1.99 (m, $J = 13.4, 8.5, 5.1$ Hz, 1H), 1.08 – 1.02 (m, 2H), 0.83 – 0.78 (m, 2H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.8, 153.9, 146.9, 133.3, 133.2, 130.3, 130.0, 129.5, 125.2, 123.6, 113.5, 29.3, 15.6, 9.8. HRMS (ESI-TOF) *m/z*: [M + Na] $^+$ Calcd for C₁₈H₁₆N₂NaO, 299.1155; Found: 299.1159.

*3-(4-benzylphenyl)-1-methylquinoxalin-2(1*H*)-one (62)⁶¹*



Light yellow solid (23.3 mg, 71%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.25 (d, $J = 8.2$ Hz, 2H), 7.95 – 7.90 (m, 1H), 7.58 – 7.53 (m, 1H), 7.38 – 7.27 (m, 6H), 7.21 (m, $J = 7.3$ Hz, 3H), 4.05 (s, 2H), 3.76 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.8, 154.0, 143.6, 140.7, 134.0, 133.3, 133.2, 130.4, 130.1, 129.7, 129.0, 128.8, 128.5, 126.1, 123.7, 113.5, 41.9, 29.3.


4-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)phenethyl acetate (63)



Yellow solid (22.1 mg, 69%); m.p. 102.7 – 103.5 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.30 (d, $J = 8.2$ Hz, 2H), 7.98 – 7.93 (m, 1H), 7.61 – 7.55 (m, 1H), 7.41 – 7.33 (m, 4H), 4.34 (t, $J = 7.0$ Hz, 2H), 3.78 (s, 3H), 3.03 (t, $J = 6.9$ Hz, 2H), 2.07 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 171.0, 154.7, 153.8, 140.3, 134.5, 133.3, 133.1, 130.4, 130.2, 129.7, 128.6, 123.7, 113.6, 64.7, 35.0, 29.3, 21.0. HRMS (ESI-TOF) *m/z*: [M + Na] $^+$ Calcd for C₁₉H₁₈N₂NaO₃,


345.1210; Found: 345.1214.

3-(3,4-dimethylphenyl)-1-methylquinoxalin-2(1H)-one (64)^[7]




Light yellow solid (17.2 mg, 65%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.11 (d, *J* = 10.2 Hz, 2H), 7.96 (d, *J* = 7.7 Hz, 1H), 7.56 (t, *J* = 7.3 Hz, 1H), 7.40 – 7.31 (m, 2H), 7.28 (d, *J* = 3.5 Hz, 1H), 3.78 (s, 3H), 2.38 (s, 3H), 2.35 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.8, 154.2, 139.4, 136.2, 133.7, 133.3, 133.2, 130.5, 130.3, 129.9, 129.4, 127.2, 123.6, 113.5, 29.2, 19.9, 19.8.

3-[1,1'-biphenyl]-4-yl)-1-methylquinoxalin-2(1H)-one (65)^[6]




Yellow solid (24.5 mg, 78%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.49 – 8.45 (m, 2H), 7.99 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.77 – 7.73 (m, 2H), 7.72 – 7.68 (m, 2H), 7.62 – 7.57 (m, 1H), 7.50 (t, *J* = 7.5 Hz, 2H), 7.43 – 7.35 (m, 3H), 3.82 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.8, 153.6, 143.0, 140.6, 135.0, 133.4, 133.2, 130.5, 130.3, 130.0, 128.8, 127.7, 127.2, 126.8, 123.8, 113.6, 29.3.

3-(4'-bromo-[1,1'-biphenyl]-4-yl)-1-methylquinoxalin-2(1H)-one (66)




Yellow solid (30.3 mg, 78%); m.p. 159.8 – 160.6 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.45 (d, *J* = 8.3 Hz, 2H), 7.98 (d, *J* = 7.8 Hz, 1H), 7.69 (d, *J* = 8.3 Hz, 2H), 7.60 (m, *J* = 8.4 Hz, 3H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.42 – 7.34 (m, 2H), 3.80 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 154.7, 153.4, 141.6, 139.5, 135.4, 133.4, 133.1, 131.9, 130.5, 130.4, 130.2, 128.8, 126.5, 123.8, 122.0, 113.6, 29.3. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₁H₁₆BrN₂O, 391.0441; Found: 391.0444.

1-methyl-3-(4-phenoxyphenyl)quinoxalin-2(1H)-one (67)^[4]




Yellow solid (28.5 mg, 87%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.40 (d, $J = 8.7$ Hz, 2H), 7.95 (d, $J = 7.8$ Hz, 1H), 7.58 (t, $J = 7.4$ Hz, 1H), 7.42 – 7.34 (m, 4H), 7.18 (t, $J = 7.4$ Hz, 1H), 7.11 (d, $J = 8.6$ Hz, 4H), 3.79 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 159.4, 156.5, 154.8, 153.2, 133.2, 133.1, 131.5, 130.9, 130.3, 130.1, 129.8, 123.8, 123.7, 119.5, 117.9, 113.6, 29.3.

3-(4-methoxyphenyl)-1-methylquinoxalin-2(1H)-one (68)^{4J}




Light yellow solid (25.1 mg, 94%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.42 (d, $J = 8.9$ Hz, 2H), 7.96 – 7.90 (m, 1H), 7.58 – 7.52 (m, 1H), 7.40 – 7.31 (m, 2H), 7.02 (d, $J = 8.9$ Hz, 2H), 3.90 (s, 3H), 3.78 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 161.5, 154.8, 153.2, 133.2, 133.1, 131.4, 130.1, 129.7, 128.8, 123.6, 113.49, 113.47, 55.4, 29.3.

3-(4-isopropoxypyhenyl)-1-methylquinoxalin-2(1H)-one (69)



Yellow solid (22.9 mg, 78%); m.p. 170.4 – 170.8 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.39 – 8.35 (m, 2H), 7.90 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.56 – 7.49 (m, 1H), 7.37 – 7.28 (m, 2H), 6.97 (d, $J = 8.9$ Hz, 2H), 4.65 (m, $J = 6.1$ Hz, 1H), 3.75 (s, 3H), 1.37 (d, $J = 6.1$ Hz, 6H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 159.9, 154.8, 153.2, 133.2, 133.1, 131.4, 130.1, 129.7, 128.4, 123.6, 115.1, 113.5, 69.9, 29.2, 22.0. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₁₈H₁₉N₂O₂, 295.1441; Found: 295.1443.


3-(3,4-dimethylphenyl)-1-methylquinoxalin-2(1H)-one (70)^{8J}



Yellow solid (26.2 mg, 88%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.17 (dd, $J = 8.5, 1.9$ Hz,


1H), 8.06 (d, $J = 1.8$ Hz, 1H), 7.96 – 7.91 (m, 1H), 7.58 – 7.52 (m, 1H), 7.40 – 7.31 (m, 2H), 6.97 (d, $J = 8.6$ Hz, 1H), 4.02 (s, 3H), 3.97 (s, 3H), 3.77 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 154.8, 152.7, 151.2, 148.4, 133.09, 133.08, 130.1, 129.8, 128.9, 123.7, 123.5, 113.5, 112.4, 110.4, 56.0, 29.3.

3-(5-acetyl-2-methoxyphenyl)-1-methylquinoxalin-2(1*H*)-one (71)




Light yellow solid (9.5 mg, 31%); m.p. 163.4 – 164.4 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.16 – 8.11 (m, 1H), 8.08 (s, 1H), 7.97 (d, $J = 7.8$ Hz, 1H), 7.64 (t, $J = 7.8$ Hz, 1H), 7.41 (t, $J = 7.7$ Hz, 2H), 7.08 (d, $J = 8.7$ Hz, 1H), 3.91 (s, 3H), 3.79 (s, 3H), 2.60 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 196.3, 161.8, 156.3, 154.2, 133.8, 132.9, 131.8, 131.0, 130.7, 130.5, 130.3, 126.6, 123.7, 113.7, 111.0, 56.2, 29.4, 26.4. HRMS (ESI-TOF) m/z : [M + Na] $^+$ Calcd for C₁₈H₁₆N₂NaO₃, 331.1053; Found: 331.1059.

2-methoxy-5-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)benzonitrile (72)



Yellow solid (20.9 mg, 72%); m.p. 210.7 – 211.5 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.81 – 8.70 (m, 2H), 7.93 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.60 (ddd, $J = 8.6, 7.4, 1.5$ Hz, 1H), 7.42 – 7.34 (m, 2H), 7.06 (d, $J = 8.9$ Hz, 1H), 4.02 (s, 3H), 3.79 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 162.4, 154.5, 150.7, 135.9, 135.5, 133.3, 132.9, 130.6, 130.4, 129.0, 124.0, 116.2, 113.7, 110.7, 101.8, 56.3, 29.3. HRMS (ESI-TOF) m/z : [M + H] $^+$ Calcd for C₁₇H₁₄N₃O₂, 292.1081; Found: 292.1082.


methyl 2-methoxy-5-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)benzoate (73)



Yellow solid (23.8 mg, 73%); m.p. 131.0 – 132.2 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.94 (s, 1H), 8.65 (d, $J = 8.5$ Hz, 1H), 7.95 (d, $J = 7.8$ Hz, 1H), 7.57 (t, $J = 7.6$ Hz, 1H), 7.37 (dd, $J = 20.4, 7.9$ Hz, 2H), 7.09 (d, $J = 8.9$ Hz, 1H), 4.00 (s, 3H), 3.95 (s, 3H), 3.78 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 166.3, 160.7, 154.7, 152.0, 135.0, 133.3, 133.2, 133.0, 130.3,


130.1, 128.2, 123.8, 119.7, 113.6, 111.4, 56.2, 52.1, 29.3. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₁₈H₁₆N₂NaO₄, 347.1002; Found: 347.1009.

2-methoxy-5-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)benzaldehyde (74)




Yellow solid (15.2 mg, 52%); m.p. 195.8 – 196.2 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 10.50 (s, 1H), 8.88 (d, *J* = 2.3 Hz, 1H), 8.72 (dd, *J* = 8.8, 2.3 Hz, 1H), 7.99 – 7.89 (m, 1H), 7.62 – 7.53 (m, 1H), 7.40 – 7.32 (m, 2H), 7.08 (d, *J* = 8.9 Hz, 1H), 4.01 (s, 3H), 3.77 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.5, 163.0, 154.7, 152.0, 137.3, 133.2, 133.0, 130.9, 130.4, 130.3, 128.9, 124.5, 123.8, 113.6, 111.1, 56.0, 29.3. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₁₇H₁₅N₂O₃, 295.1077; Found: 295.1082.

1-methyl-3-(4-(2-oxopyrrolidin-1-yl)phenyl)quinoxalin-2(1H)-one (75)



Yellow solid (24.5 mg, 77%); m.p. 176.1 – 176.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.45 (d, *J* = 8.8 Hz, 2H), 7.96 – 7.91 (m, 1H), 7.78 (d, *J* = 8.9 Hz, 2H), 7.59 – 7.53 (m, 1H), 7.40 – 7.31 (m, 2H), 3.93 (t, *J* = 7.0 Hz, 2H), 3.77 (s, 3H), 2.66 (t, *J* = 8.1 Hz, 2H), 2.19 (q, *J* = 7.7 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 174.5, 154.8, 152.9, 141.2, 133.2, 133.1, 131.8, 130.34, 130.32, 130.1, 123.7, 118.7, 113.5, 48.6, 32.9, 29.3, 17.9. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₁₉H₁₇N₃NaO₂, 342.1213; Found: 342.1214.


1-(4-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)phenyl)pyrrolidine-2,5-dione (76)



Yellow solid (25.9 mg, 78%); m.p. 262.0 – 262.6 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.35 (d, *J* = 8.5 Hz, 2H), 7.93 – 7.89 (m, 1H), 7.71 – 7.66 (m, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.43 (dd, *J* = 11.7, 8.0 Hz, 3H), 3.72 (s, 3H), 2.83 (s, 4H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 177.3, 154.4, 152.9, 136.0, 134.7, 133.8, 132.7, 131.3, 130.2, 130.1, 126.8, 124.2, 115.3, 29.8, 29.0.


HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₁₉H₁₅N₃NaO₃, 356.1006; Found: 356.1008.

N-(4-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)phenyl)benzamide (77)




Yellow solid (26.2 mg, 74%); m.p. 208.2 – 208.8 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.48 (s, 1H), 8.37 (d, *J* = 8.8 Hz, 2H), 8.01 (d, *J* = 7.1 Hz, 2H), 7.95 (d, *J* = 8.8 Hz, 2H), 7.89 – 7.85 (m, 1H), 7.66 – 7.60 (m, 2H), 7.59 – 7.53 (m, 3H), 7.43 – 7.38 (m, 1H), 3.70 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 166.2, 154.5, 152.5, 141.6, 135.2, 133.6, 132.8, 132.2, 131.5, 130.7, 130.5, 129.9, 128.9, 128.2, 124.0, 119.7, 115.1, 29.7. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₂₂H₁₇N₃NaO₂, 378.1213; Found: 378.1217.

3-(4-acetylphenyl)-1-methylquinoxalin-2(1H)-one (78)^[5]




Yellow solid (19.2 mg, 69%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.46 (d, *J* = 8.5 Hz, 2H), 8.07 (d, *J* = 8.5 Hz, 2H), 8.00 – 7.95 (m, 1H), 7.66 – 7.60 (m, 1H), 7.44 – 7.36 (m, 2H), 3.80 (s, 3H), 2.67 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 197.9, 154.6, 152.8, 140.3, 137.9, 133.5, 133.0, 131.0, 130.7, 129.8, 127.9, 123.9, 113.7, 29.4, 26.8.

3-(4-fluorophenyl)-1-methylquinoxalin-2(1H)-one (79)^[4]




Yellow solid (16.0 mg, 63%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.47 – 8.38 (m, 2H), 7.95 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.59 (ddd, *J* = 8.6, 7.4, 1.5 Hz, 1H), 7.43 – 7.33 (m, 2H), 7.21 – 7.14 (m, 2H), 3.79 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 164.2 (d, *J* = 251.0 Hz), 154.7, 152.7, 133.3, 133.0, 132.2 (d, *J* = 3.2 Hz), 131.8 (d, *J* = 8.5 Hz), 130.4 (d, *J* = 2.7 Hz), 123.8, 115.2, 114.9, 113.6, 29.3. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -110.04.

3-(4-chlorophenyl)-1-methylquinoxalin-2(1H)-one (80)^[4]




Yellow solid (17.0 mg, 63%); ^1H NMR (400 MHz, Chloroform-d) δ 8.37 (d, $J = 8.5$ Hz, 2H), 7.94 (d, $J = 7.8$ Hz, 1H), 7.59 (t, $J = 7.5$ Hz, 1H), 7.46 (d, $J = 8.5$ Hz, 2H), 7.42 – 7.33 (m, 2H), 3.78 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-d) δ 154.6, 152.6, 136.5, 134.4, 133.4, 133.0, 131.0, 130.55, 130.48, 128.3, 123.8, 113.6, 29.3.

3-(4-bromophenyl)-1-methylquinoxalin-2(1H)-one (81)^[4]




Yellow solid (17.9 mg, 57%); ^1H NMR (400 MHz, Chloroform-d) δ 8.32 – 8.25 (m, 2H), 7.94 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.64 – 7.57 (m, 3H), 7.41 – 7.33 (m, 2H), 3.78 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-d) δ 154.5, 152.7, 134.9, 133.4, 133.0, 131.23, 131.20, 130.6, 130.5, 125.1, 123.9, 113.6, 29.3.

1-methyl-3-(4-(trifluoromethyl)phenyl)quinoxalin-2(1H)-one (82)^[4]



Yellow solid (23.1 mg, 76%); ^1H NMR (400 MHz, Chloroform-d) δ 8.48 (d, $J = 8.2$ Hz, 2H), 7.96 (d, $J = 8.0$ Hz, 1H), 7.74 (d, $J = 8.3$ Hz, 2H), 7.61 (t, $J = 7.8$ Hz, 1H), 7.44 – 7.32 (m, 2H), 3.77 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-d) δ 154.5, 152.4, 139.3 (d, $J = 1.5$ Hz), 133.5, 132.9, 131.7 (q, $J = 32.3$ Hz), 131.0, 130.7, 129.9, 124.9 (q, $J = 3.9$ Hz), 124.1 (q, $J = 272.3$ Hz), 123.9, 113.7, 29.3. ^{19}F NMR (376 MHz, Chloroform-d) δ -62.80.


2,2,2-trifluoro-N-(4-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)phenyl)acetamide (83)



Yellow solid (22.6 mg, 65%); m.p. 205.1 – 206.2 °C; ^1H NMR (400 MHz, DMSO- d_6) δ 8.39 – 8.34 (m, 2H), 7.88 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.84 – 7.79 (m, 2H), 7.66 (ddd, $J = 8.5, 7.1, 1.5$


Hz, 1H), 7.59 (dd, $J = 8.4$, 1.0 Hz, 1H), 7.44 – 7.39 (m, 1H), 3.70 (s, 3H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 155.1 (q, $J = 37.4$ Hz), 154.4, 152.3, 138.5, 133.7, 133.4, 132.7, 131.0, 130.6, 130.0, 124.1, 120.6, 116.2 (q, $J = 289.0$ Hz), 115.2, 29.7. ^{19}F NMR (376 MHz, DMSO- d_6) δ -73.85. HRMS (ESI-TOF) m/z : [M + Na] $^+$ Calcd for $\text{C}_{17}\text{H}_{12}\text{F}_3\text{N}_3\text{NaO}_2$, 370.0774; Found: 370.0777.

3-methoxy-4-(3-(2-oxo-3-(*p*-tolyl)quinoxalin-1(2*H*)-yl)propoxy)benzaldehyde (84)



Light yellow solid (23.3 mg, 54%); m.p. 172.7 – 173.1 °C; ^1H NMR (400 MHz, Chloroform- d) δ 9.86 (s, 1H), 8.08 (d, $J = 8.1$ Hz, 1H), 8.01 (d, $J = 7.9$ Hz, 2H), 7.83 (d, $J = 8.2$ Hz, 1H), 7.65 (t, $J = 7.5$ Hz, 1H), 7.58 (t, $J = 7.4$ Hz, 1H), 7.42 (d, $J = 5.9$ Hz, 2H), 7.29 (d, $J = 7.8$ Hz, 2H), 6.97 (d, $J = 8.5$ Hz, 1H), 4.81 (t, $J = 6.0$ Hz, 2H), 4.33 (d, $J = 6.3$ Hz, 2H), 3.91 (s, 3H), 2.47 (m, $J = 11.7$ Hz, 5H). ^{13}C NMR (101 MHz, Chloroform- d) δ 190.8, 155.3, 153.9, 149.9, 146.5, 139.8, 139.7, 139.0, 133.3, 130.2, 129.53, 129.49, 128.9, 126.8, 126.58, 126.55, 111.6, 109.5, 66.1, 63.2, 56.0, 28.6, 21.4. HRMS (ESI-TOF) m/z : [M + Na] $^+$ Calcd for $\text{C}_{26}\text{H}_{24}\text{N}_2\text{NaO}_4$, 451.1628; Found: 451.1632.


3-methoxy-2-(3-(2-oxo-3-(*p*-tolyl)quinoxalin-1(2*H*)-yl)propoxy)benzaldehyde (85)



White solid (20.5 mg, 48%); m.p. 116.7 – 118.1 °C; ^1H NMR (400 MHz, Chloroform- d) δ 10.49 (s, 1H), 8.08 (d, $J = 8.1$ Hz, 1H), 8.04 (d, $J = 8.1$ Hz, 2H), 7.88 (d, $J = 8.1$ Hz, 1H), 7.69 – 7.64 (m, 1H), 7.62 – 7.57 (m, 1H), 7.45 (dd, $J = 5.6$, 3.8 Hz, 1H), 7.30 (d, $J = 8.8$ Hz, 2H), 7.17 – 7.12 (m, 2H), 4.84 (t, $J = 6.2$ Hz, 2H), 4.37 (t, $J = 6.3$ Hz, 2H), 3.80 (s, 3H), 2.43 (m, $J = 12.4$ Hz, 5H). ^{13}C NMR (101 MHz, Chloroform- d) δ 190.0, 155.4, 153.0, 151.7, 146.5, 139.764,


139.756, 139.0, 133.3, 130.0, 129.6, 129.5, 128.9, 126.69, 126.68, 124.1, 119.3, 118.1, 71.8, 63.4, 56.0, 29.6, 21.4. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₂₆H₂₄N₂NaO₄, 451.1628; Found: 451.1637.

1-(3-(2-methoxy-4-(3-oxobutyl)phenoxy)propyl)-3-(*p*-tolyl)quinoxalin-2(1*H*)-one (86)




White solid (30.1 mg, 64%); m.p. 88.9 – 90.1 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.08 (d, *J* = 8.1 Hz, 1H), 8.02 (d, *J* = 8.0 Hz, 2H), 7.85 (d, *J* = 8.2 Hz, 1H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.30 (d, *J* = 9.0 Hz, 2H), 6.82 (d, *J* = 8.1 Hz, 1H), 6.76 – 6.65 (m, 2H), 4.79 (t, *J* = 6.0 Hz, 2H), 4.23 (t, *J* = 6.3 Hz, 2H), 3.84 (s, 3H), 2.89 – 2.82 (m, 2H), 2.75 (t, *J* = 7.3 Hz, 2H), 2.46 (s, 3H), 2.44 – 2.39 (m, 2H), 2.16 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 208.1, 155.4, 149.5, 146.7, 146.6, 139.8, 139.7, 139.0, 134.2, 133.3, 129.6, 129.4, 128.93, 128.90, 126.65, 126.63, 120.2, 113.7, 112.3, 66.2, 63.6, 55.9, 45.4, 30.1, 29.4, 28.8, 21.5. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₂₉H₃₁N₂O₄, 471.2278; Found: 471.2277.

2-(2-oxo-3-(*p*-tolyl)quinoxalin-1(2*H*)-yl)ethyl 2-(4-isobutylphenyl)propanoate (87)




Colourless oil (37.8 mg, 81%); m.p. 96.5 – 98.2 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.27 (d, *J* = 8.2 Hz, 2H), 7.95 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.48 – 7.52 (m, 1H), 7.44 – 7.30 (m, 4H), 7.13 – 7.04 (m, 4H), 4.64 – 4.44 (m, 4H), 3.63 (q, *J* = 7.2 Hz, 1H), 2.41 – 2.48 (m, 5H), 1.80 – 1.90 (m, 1H), 1.45 (d, *J* = 7.2 Hz, 3H), 0.91 (d, *J* = 6.6 Hz, 6H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 174.7, 154.6, 153.7, 140.74, 140.69, 137.2, 133.3, 133.1, 132.8, 130.5, 130.1, 129.5, 129.4, 128.8, 127.1, 123.7, 113.7, 61.2, 45.03, 45.01, 41.1, 30.1, 22.4, 21.5, 18.3. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₃₀H₃₃N₂O₃, 469.2486; Found: 469.2496.

2-(2-oxo-3-(*p*-tolyl)quinoxalin-1(2H)-yl)ethyl-2-(11-oxo-6,11-dihydrodibenz[b,e]oxepin-2-yl)acetate (88)



Yellow solid (37.6 mg, 71%); m.p. 136.4–137.6 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.28 (d, J = 8.2 Hz, 2H), 8.07 (d, J = 2.3 Hz, 1H), 7.92 (ddd, J = 10.2, 7.9, 1.3 Hz, 2H), 7.61 – 7.29 (m, 10H), 6.98 (d, J = 8.4 Hz, 1H), 5.19 (s, 2H), 4.62 (t, J = 6.0 Hz, 2H), 4.55 (t, J = 5.5 Hz, 2H), 3.60 (s, 2H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 190.7, 171.4, 160.5, 154.6, 153.7, 140.7, 140.4, 136.3, 135.5, 133.3, 133.1, 132.80, 132.76, 132.5, 130.6, 130.2, 129.6, 129.5, 129.3, 128.8, 127.8, 127.2, 125.1, 123.8, 121.2, 113.5, 73.6, 61.3, 41.1, 40.0, 21.5. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₃H₂₇N₂O₅, 531.1914; Found: 531.1920.


1-methyl-3-(4-(4-(2-(pyridin-2-yl)phenoxy)propoxy)phenoxy)phenylquinoxalin-2(1H)-one (89)



Yellow solid (28.6 mg, 60%); m.p. 87.4 – 89.1 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.37 (d, J = 8.7 Hz, 2H), 8.18 (d, J = 3.9 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.58 (q, J = 8.2 Hz, 2H), 7.40 – 7.32 (m, 2H), 7.04 (d, J = 6.9 Hz, 4H), 6.98 (d, J = 9.0 Hz, 2H), 6.91 – 6.86 (m, 1H), 6.77 (d, J = 8.3 Hz, 1H), 5.67 – 5.59 (m, 1H), 4.23 (dd, J = 9.8, 5.3 Hz, 1H), 4.12 (dd, J = 9.8, 4.8 Hz, 1H), 3.78 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 163.2, 160.5, 155.6, 154.8, 153.2, 149.6, 146.8, 138.7, 133.2, 133.1, 131.4, 130.3, 130.2, 130.0, 123.7, 121.2, 116.8, 116.7, 115.9, 113.5, 111.7, 71.1, 69.3, 29.3, 17.0. HRMS (ESI-TOF) *m/z*: [M +


$\text{Na}]^+$ Calcd for $\text{C}_{29}\text{H}_{25}\text{N}_3\text{NaO}_4$, 502.1737; Found: 502.1744.

Methyl-2-(2-fluoro-4'-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)-[1,1'-biphenyl]-4-yl)propanoate (90)



Yellow solid (36.2 mg, 87%); m.p. 133.3 – 133.8 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 8.45 (d, *J* = 8.4 Hz, 2H), 7.97 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.69 (dd, *J* = 8.3, 1.3 Hz, 2H), 7.62 – 7.56 (m, 1H), 7.48 (t, *J* = 8.0 Hz, 1H), 7.43 – 7.33 (m, 2H), 7.23 – 7.13 (m, 2H), 3.80 (q, *J* = 7.4 Hz, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 1.57 (d, *J* = 7.2 Hz, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 174.4, 159.8 (d, *J* = 249.2 Hz), 154.7, 153.5, 142.2 (d, *J* = 7.6 Hz), 137.4 (d, *J* = 1.5 Hz), 135.4, 133.4, 133.2, 130.8 (d, *J* = 3.7 Hz), 130.5, 130.4, 129.7, 128.6 (d, *J* = 3.1 Hz), 127.4 (d, *J* = 13.3 Hz), 123.7, 123.6 (d, *J* = 3.3 Hz), 115.4 (d, *J* = 23.6 Hz), 113.6, 52.2, 45.0 (d, *J* = 1.5 Hz), 29.3, 18.4. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -116.84. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for $\text{C}_{25}\text{H}_{22}\text{FN}_2\text{O}_3$, 417.1609; Found: 417.1608.


2-chloro-N-(4'-chloro-5-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)-[1,1'-biphenyl]-2-yl)nicotinamide (91)



Yellow solid (30.8 mg, 62%); m.p. 162.1 – 163.9 °C; ^1H NMR (400 MHz, DMSO-*d*₆) δ 10.29 (s, 1H), 8.50 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.42 – 8.25 (m, 2H), 7.98 – 7.87 (m, 2H), 7.82 (d, *J* = 8.4 Hz, 1H), 7.70 – 7.63 (m, 1H), 7.60 (d, *J* = 7.9 Hz, 1H), 7.55 (m, 5H), 7.45 – 7.39 (m, 1H), 3.71 (s, 3H). ^{13}C NMR (101 MHz, DMSO-*d*₆) δ 164.6, 154.5, 152.4, 150.8, 146.9, 138.4, 138.0, 136.3, 135.5, 134.5, 133.7, 133.4, 132.8, 132.7, 131.9, 131.24, 131.16, 130.1, 129.6, 128.9, 126.6, 124.1, 123.5, 115.2, 29.7. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for $\text{C}_{27}\text{H}_{19}\text{Cl}_2\text{N}_4\text{O}_2$, 501.0880; Found: 501.0882.


2,2,2-trifluoro-N-methyl-N-(3-(2-methyl-4-(4-methyl-3-oxo-3,4-dihydroquinoxalin-

2-(2-*tert*-butylphenoxy)-3-phenylpropylacetamide (92)




Colorless oil (37.6mg, 74%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.25 – 8.16 (m, 1H), 8.07 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.88 (d, *J* = 7.9 Hz, 1H), 7.50 (t, *J* = 7.8 Hz, 1H), 7.38 – 7.26 (m, 7H), 6.69 (dd, *J* = 16.0, 8.7 Hz, 1H), 5.33 (dd, *J* = 8.0, 4.4 Hz, 1H), 3.81 – 3.64 (m, 5H), 3.16 – 3.03 (m, 3H), 2.46 (d, *J* = 3.7 Hz, 3H), 2.37 – 2.23 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 157.5, 157.3, 157.1, 157.0, 156.73, 156.68, 154.7, 153.34, 153.28, 140.6, 140.2, 133.12, 133.07, 132.11, 132.07, 130.0, 129.74, 129.70, 128.9, 128.83, 128.79, 128.7, 128.6, 128.1, 128.0, 126.53, 126.50, 125.6, 125.5, 123.6, 123.58, 118.0, 117.9, 115.1, 115.0, 113.5, 112.1, 112.0, 47.1, 46.59, 46.56, 37.5, 35.60, 35.56, 35.49, 35.41, 35.38, 34.8, 29.2, 16.7, 16.6. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -68.94, -69.85. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₈H₂₆F₃N₃NaO₃, 532.1818; Found: 532.1816.

***N*-(2,6-dimethyl-4-(4-methyl-3-oxo-3,4-dihydroquinalin-2-yl)phenyl)-2-(2-oxopyrrolidin-1-yl)acetamide (93)**




Yellow solid (29.1 mg, 72%); m.p. 116.0 – 116.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.11 (s, 1H), 8.04 (s, 2H), 7.91 (d, *J* = 7.8 Hz, 1H), 7.54 (t, *J* = 7.6 Hz, 1H), 7.34 (dd, *J* = 16.0, 8.5 Hz, 2H), 4.12 (s, 2H), 3.73 (s, 3H), 3.61 (t, *J* = 7.0 Hz, 2H), 2.46 (t, *J* = 8.1 Hz, 2H), 2.28 (s, 6H), 2.11 (d, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 176.3, 166.8, 154.6, 153.3, 135.6, 134.77, 134.75, 133.2, 133.0, 130.4, 130.2, 129.4, 123.7, 113.5, 48.6, 47.5, 30.4, 29.3, 18.6, 18.1. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ Calcd for C₂₃H₂₄N₄NaO₃, 427.1741; Found: 427.1740.

***N*-(4-chlorophenyl)-2-(2-oxo-3-phenylquinalin-1(2*H*)-yl)acetamide (94)^[9]**




Yellow solid (27.9 mg, 72%); ^1H NMR (400 MHz, DMSO- d_6) δ 10.63 (s, 1H), 8.30 – 8.24 (m, 2H), 7.95 (dd, J = 8.0, 1.5 Hz, 1H), 7.67 – 7.58 (m, 4H), 7.55 – 7.49 (m, 3H), 7.46 – 7.42 (m, 1H), 7.41 – 7.37 (m, 2H), 5.22 (s, 2H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 165.5, 154.4, 153.3, 138.0, 136.1, 133.6, 132.8, 131.2, 130.8, 130.2, 129.8, 129.2, 128.4, 127.6, 124.2, 121.2, 115.2, 46.1.

*3-(*p*-tolyl)-2*H*-chromen-2-one (95)^[10]*




White solid (11.1 mg, 47%); ^1H NMR (400 MHz, Chloroform- d) δ 7.81 (s, 1H), 7.64 (d, J = 8.1 Hz, 2H), 7.57 – 7.52 (m, 2H), 7.38 (d, J = 8.1 Hz, 1H), 7.33 – 7.27 (m, 3H), 2.42 (s, 3H). ^{13}C NMR (101 MHz, Chloroform- d) δ 160.7, 153.4, 139.2, 138.9, 131.8, 131.2, 129.2, 128.4, 128.3, 127.8, 124.4, 119.8, 116.4, 21.3.

*1-(fluoromethyl)-3-(*p*-tolyl)cinnolin-4(1*H*)-one (96)*




White solid (16.4 mg, 61%); m.p. 106.5 – 107.9 °C; ^1H NMR (400 MHz, Chloroform- d) δ 8.48 – 8.40 (m, 1H), 8.04 (d, J = 8.2 Hz, 2H), 7.79 (ddd, J = 8.6, 7.2, 1.4 Hz, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.31 – 7.28 (m, 2H), 6.45 (s, 1H), 6.32 (s, 1H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, Chloroform- d) δ 170.7, 147.3 (d, J = 2.7 Hz), 140.5 (d, J = 2.9 Hz), 139.4, 134.2, 130.7, 128.8 (d, J = 21.1 Hz), 126.8, 125.4, 124.3, 114.3, 93.0, 91.0, 21.4. ^{19}F NMR (376 MHz, Chloroform- d) δ -170.13. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₁₆H₁₄FN₂O, 269.1085; Found: 269.1090.

*2-phenyl-3-(*p*-tolyl)imidazo[1,2-*a*]pyridine (97)^[11]*




Brown Solid (11.0 mg, 39%); ^1H NMR (400 MHz, Chloroform-*d*) δ 7.97 – 7.95 (m, 1H), 7.74 – 7.68 (m, 3H), 7.36 – 7.18 (m, 8H), 6.75 – 6.71 (m, 1H), 2.48 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 144.7, 142.2, 138.8, 134.3, 130.6, 130.3, 128.2, 128.0, 127.4, 126.8, 124.5, 123.3, 121.1, 117.5, 112.1, 21.5.

3-methyl-1-phenyl-4-(p-tolyl)-1H-pyrrole-2,5-dione compound with methane (98)




Yellow solid (10.1 mg, 34%); m.p. 138.3–139.4 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.58 (d, J = 8.2 Hz, 2H), 7.52 – 7.47 (m, 2H), 7.46 – 7.42 (m, 2H), 7.40 – 7.36 (m, 1H), 7.34 (d, J = 8.1 Hz, 2H), 2.45 (s, 3H), 2.31 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 170.9, 169.9, 140.1, 137.2, 135.9, 131.9, 129.6, 129.4, 129.0, 127.6, 126.0, 21.5, 10.2. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₁₉H₂₀NO₂, 294.1489; Found: 294.1499.

5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)-3-(p-tolyl)-4H-chromen-4-one (99)



White solid (16.7 mg, 36%); m.p. 170.5 – 171.3 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.43 – 7.36 (m, 2H), 7.19 – 7.11 (m, 4H), 6.84 – 6.76 (m, 2H), 4.13 (s, 3H), 4.02 (s, 3H), 3.97 (s, 3H), 3.94 (s, 3H), 3.82 (s, 3H), 2.37 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 176.4, 160.8, 158.9, 151.2, 148.6, 147.5, 144.0, 137.8, 137.2, 131.1, 131.0, 130.1, 129.2, 125.4, 122.0, 114.5, 113.5, 62.2, 62.0, 61.8, 61.7, 55.3, 21.3. HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for C₂₇H₂₇O₇, 463.1751; Found: 463.1754.


2,4,6-trimethoxy-4'-methyl-1,1'-biphenyl (100)^[12]




White solid (15.8 mg, 61%); ^1H NMR (400 MHz, Chloroform-*d*) δ 7.28 – 7.20 (m, 4H), 6.26

(s, 2H), 3.89 (s, 3H), 3.75 (s, 6H), 2.41 (s, 3H). ^{13}C NMR (101 MHz, Chloroform-*d*) δ 160.3, 158.4, 136.0, 131.0, 131.0, 128.5, 112.4, 90.9, 55.9, 55.4, 21.4.


5. NMR Copies of Products




8.02
8.01
8.01
8.00
8.00
7.99
7.98
7.98
7.59
7.58
7.57
7.56
7.52
7.51
7.50
7.49
7.48
7.47
7.47
7.46
7.45
7.45
7.42
7.42
7.41
7.40
7.38
7.38
7.37
7.37
7.36
7.36
7.34
7.34
7.33
7.32
5.25
5.21




4: ^1H NMR
400 MHz, CDCl_3










-155.47
-148.80
-141.83
-135.64
-135.61
-132.04
-132.03
-130.03
-129.59
-128.84
-128.79
-128.60
-128.44
-128.33
-128.28
-128.11
-7.38
-7.33
-7.32
-5.25
-5.21





4: ^{13}C NMR
101 MHz, CDCl_3















8.12
8.07
8.05
7.89
7.87
7.76
7.74
7.73
7.58
7.56
7.54
7.50
7.50
7.49
7.48
7.46
7.46
7.41
7.41
7.39
7.37
7.37
7.35
7.33
7.31
5.23
5.18




-165.83
-155.53
-148.76
-148.38
-139.66
-135.62
-135.59
-134.73
-132.02
-129.49
-129.29
-128.86
-128.81
-128.61
-128.35
-128.11
-128.01
-127.11
-119.51


-55.74
-44.49



7.92
7.91
7.90
7.59
7.59
7.58
7.58
7.56
7.56
7.54
7.49
7.49
7.47
7.47
7.41
7.39
7.38
7.37
7.36
7.35
7.34
7.33
7.32
5.19




10: ^1H NMR
400 MHz, CDCl_3




— 155.28
— 148.68
— 148.07
— 135.48
— 135.42
— 131.49
— 130.91
— 129.89
— 129.57
— 128.84
— 128.83
— 128.62
— 128.42
— 128.18
— 124.64




— 55.81
— 44.56








10: ^{13}C NMR
101 MHz, CDCl_3




7.80
7.79
7.78
7.78
7.77
7.76
7.75
7.74
7.73
7.72
7.71
7.70
7.69
7.68
7.67
7.66
7.65
7.64
7.63
7.62
7.61
7.60
7.59
7.58
7.57
7.56
7.55
7.54
7.53
7.52
7.51
7.50
7.49
7.48
7.47
7.46
7.45
7.44
7.43
7.42
7.41
7.40
7.39
7.38
7.37
7.36
7.35
7.34
7.33
7.32
7.31
7.30
7.29
7.28
7.27
7.26
7.25
7.24
7.23
7.22
7.21
7.20
7.19
7.18
7.17
7.16
7.15
7.14
7.13
7.12
7.11
7.10
7.09
7.08
7.07
7.06
7.05
7.04
7.03
7.02
7.01
7.00
6.99
6.98
6.97
6.96
6.95
6.94
6.93
6.92
6.91
6.90
6.89
6.88
6.87
6.86
6.85
6.84
6.83
6.82
6.81
6.80
6.79
6.78
6.77
6.76
6.75
6.74
6.73
6.72
6.71
6.70
6.69
6.68
6.67
6.66
6.65
6.64
6.63
6.62
6.61
6.60
6.59
6.58
6.57
6.56
6.55
6.54
6.53
6.52
6.51
6.50
6.49
6.48
6.47
6.46
6.45
6.44
6.43
6.42
6.41
6.40
6.39
6.38
6.37
6.36
6.35
6.34
6.33
6.32
6.31
6.30
6.29
6.28
6.27
6.26
6.25
6.24
6.23
6.22
6.21
6.20
6.19
6.18
6.17
6.16
6.15
6.14
6.13
6.12
6.11
6.10
6.09
6.08
6.07
6.06
6.05
6.04
6.03
6.02
6.01
6.00
5.99
5.98
5.97
5.96
5.95
5.94
5.93
5.92
5.91
5.90
5.89
5.88
5.87
5.86
5.85
5.84
5.83
5.82
5.81
5.80
5.79
5.78
5.77
5.76
5.75
5.74
5.73
5.72
5.71
5.70
5.69
5.68
5.67
5.66
5.65
5.64
5.63
5.62
5.61
5.60
5.59
5.58
5.57
5.56
5.55
5.54
5.53
5.52
5.51
5.50
5.49
5.48
5.47
5.46
5.45
5.44
5.43
5.42
5.41
5.40
5.39
5.38
5.37
5.36
5.35
5.34
5.33
5.32
5.31
5.30
5.29
5.28
5.27
5.26
5.25
5.24
5.23
5.22
5.21
5.20
5.19
5.18
5.17
5.16
5.15
5.14
5.13
5.12
5.11
5.10
5.09
5.08
5.07
5.06
5.05
5.04
5.03
5.02
5.01
5.00
4.99
4.98
4.97
4.96
4.95
4.94
4.93
4.92
4.91
4.90
4.89
4.88
4.87
4.86
4.85
4.84
4.83
4.82
4.81
4.80
4.79
4.78
4.77
4.76
4.75
4.74
4.73
4.72
4.71
4.70
4.69
4.68
4.67
4.66
4.65
4.64
4.63
4.62
4.61
4.60
4.59
4.58
4.57
4.56
4.55
4.54
4.53
4.52
4.51
4.50
4.49
4.48
4.47
4.46
4.45
4.44
4.43
4.42
4.41
4.40
4.39
4.38
4.37
4.36
4.35
4.34
4.33
4.32
4.31
4.30
4.29
4.28
4.27
4.26
4.25
4.24
4.23
4.22
4.21
4.20
4.19
4.18
4.17
4.16
4.15
4.14
4.13
4.12
4.11
4.10
4.09
4.08
4.07
4.06
4.05
4.04
4.03
4.02
4.01
4.00











165.09
162.60
155.43
148.73
140.19
135.55
135.53
130.53
130.44
129.56
128.81
128.61
128.38
128.15
115.45
115.24
- 55.75
- 44.55









13: ^{13}C NMR
101 MHz, CDCl_3






























20: ^1H NMR
400 MHz, CDCl_3





20: ^{13}C NMR
101 MHz, CDCl_3
















22: ^{13}C NMR
101 MHz, CDCl_3







23: ^1H NMR
400 MHz, CDCl_3





























29: ^1H NMR
400 MHz, CDCl_3






29: ^{13}C NMR
101 MHz, CDCl_3















32: ^{19}F NMR
376 MHz, CDCl_3








33: ^1H NMR
400 MHz, CDCl_3









7.74
7.72
7.35
7.34
7.32
7.32
7.31
7.31
7.30
7.29
7.29
7.28
7.27
7.27
7.24
7.24
7.23
7.23
7.22
7.20
6.48
6.49
4.70
4.68
4.66
4.65
4.62
4.61
4.59
4.58
4.54
4.51
4.49
4.46
4.41
4.41
4.41
4.40
4.39
4.39
4.38
4.33
4.31
4.30
3.68
3.67
3.65
3.64
3.63
3.61
3.60
3.59
3.40
2.43
















36: ¹³C NMR
101 MHz, CDCl₃







36: ¹⁹F NMR
376 MHz, CDCl₃




8.48
8.47
8.47
8.37
8.21
8.21
8.19
8.19
8.14
8.14
8.12
8.11
7.99
7.99
7.56
7.55
7.54
7.53
7.49
7.49
7.47
7.46
7.41
7.41
7.40
7.40
7.39
7.38
7.37
7.36
7.35
7.33
7.33
6.44
6.43
5.79
5.78
5.58
5.57
5.55
5.18
4.38
4.38
4.37
4.34
4.33
4.18
4.17
4.15
4.13
2.14
2.12
1.86









38: ^{19}F NMR
376 MHz, CDCl_3





8.19
8.18
8.18
7.78
7.76
7.60
7.36
7.35
7.33
7.32
7.32
7.31
7.30
7.29
7.28
7.28
7.26
7.26
7.25
7.25
7.24
7.24
7.23
7.23
7.22
7.22
7.21
7.20
7.03
7.03
7.02
7.02
6.89
6.87
6.87
6.79
6.79
6.77
6.77
6.50
6.49
6.49
4.71
4.71
4.70
4.70
4.68
4.68
4.67
4.67
4.64
4.64
4.60
4.60
4.57
4.57
4.50
4.50
4.48
4.48
4.40
4.40
4.39
4.39
4.33
4.33
4.14
4.14
3.66
3.66
3.65
3.65
3.63
3.63
3.62
3.62
3.40
3.40
1.54
1.54






39: ^1H NMR
400 MHz, CDCl_3






















































164.53
162.04
154.59
152.81
152.77
140.69
134.73
134.61
133.07
132.23
132.13
129.90
129.88
129.41
128.85
111.64
111.41
100.59
100.32


-29.52
-21.52




54: ^{13}C NMR
101 MHz, CDCl_3







-107.45







54: ^{19}F NMR
376 MHz, CDCl_3
















57: ^{19}F NMR
376 MHz, CDCl_3




- 12.53


8.28
8.26
7.83
7.81
7.54
7.52
7.50
7.34
7.33
7.32
7.31
7.29


- 2.38






58: ^1H NMR
400 MHz, $\text{DMSO}-d_6$































159.43
 156.52
 154.76
 153.16

133.25
 133.13
 131.48
 130.93
 130.30
 130.08
 129.84
 123.79
 123.73
 119.53
 117.85
 113.56


- 29.31




67: ^{13}C NMR
 101 MHz, CDCl_3




8.43
 8.41
 7.94
 7.92
 7.92
 7.57
 7.57
 7.55
 7.53
 7.53
 7.39
 7.37
 7.35
 7.34
 7.32
 7.03
 7.03
 7.01
 133.25
 133.13
 131.48
 130.93
 130.30
 130.08
 129.84
 123.79
 123.73
 119.53
 117.85
 113.56
 -29.31




68: ^1H NMR
 400 MHz, CDCl_3




\sim 161.47
 \diagup 154.83
 \diagdown 153.19
 133.17
 \diagup 133.13
 \diagdown 131.37
 130.13
 \diagup 129.74
 \diagdown 128.76
 123.64
 \diagup 113.49
 \diagdown 113.47




68: ^{13}C NMR
101 MHz, CDCl_3






8.39
8.38
8.38
8.36
8.36
8.36
8.36
7.91
7.91
7.89
7.89
7.89
7.89
7.54
7.53
7.51
7.51
7.49
7.49
7.36
7.36
7.34
7.32
7.32
7.32
7.31
7.31
7.28
7.28
6.98
6.98
6.96
6.96
4.70
4.68
4.68
4.67
4.67
4.65
4.64
4.64
4.62
4.62
4.61
4.61
-3.75
-55.38
 \diagup 1.38
 \diagdown 1.36





69: ^1H NMR
400 MHz, CDCl_3


















\sim 8.94
 \swarrow
 \sim 8.66
 \swarrow
 \sim 8.64
 \nearrow
 7.96
 \nearrow
 \sim 7.94
 \nearrow
 \sim 7.59
 \nearrow
 \sim 7.57
 \nearrow
 \sim 7.55
 \nearrow
 \sim 7.40
 \nearrow
 \sim 7.39
 \nearrow
 \sim 7.35
 \nearrow
 \sim 7.33
 \nearrow
 \sim 7.28
 \nearrow
 \sim 7.28
 \nearrow
 \sim 7.10
 \nearrow
 \sim 7.08
 \nearrow
 \sim 4.00
 \swarrow
 \sim 3.95
 \swarrow
 \sim 3.78



















165.44
162.95
154.66
152.74
133.30
132.19
132.16
131.87
131.79
130.39
130.37
123.82
115.15
114.94
113.60


-29.32




79: ^{13}C NMR
101 MHz, CDCl_3







-110.04




79: ^{19}F NMR
376 MHz, CDCl_3















81: ^{13}C NMR
101 MHz, CDCl_3

















84: ^1H NMR
400 MHz, CDCl_3






84: ^{13}C NMR
101 MHz, CDCl_3























90: ^1H NMR
400 MHz, CDCl_3





90: ^{13}C NMR
101 MHz, CDCl_3








90: ^{19}F NMR
376 MHz, CDCl_3








91: ^1H NMR
400 MHz, DMSO- d_6








157.50
157.39
157.33
157.08
157.04
156.73
156.68
156.33
154.74
153.34
153.28
140.61
140.21
133.12
133.07
132.11
132.07
130.03
129.74
129.70
128.93
128.83
128.79
128.66
128.58
128.09
127.96
126.53
126.50
125.63
125.48
123.60
123.58
118.00
117.88
115.14
115.01
113.50
112.12
111.96
47.10
46.59
46.56
37.45
35.56
35.49
35.45
35.41
35.38
34.78
29.19
16.67
16.57















160.69
 153.45
 139.20
 138.93
 131.83
 131.19
 129.19
 128.41
 128.34
 127.81
 124.44
 119.79
 116.43
 -21.30











96: ^{19}F NMR
376 MHz, CDCl_3






97: ^1H NMR
400 MHz, CDCl_3











6. Reference

- [1] P. Ghosh, N. Y. Kwon, S. Kim, S. Han, S. H. Lee, W. An, N. K. Mishra, S. B. Han, I. S. Kim, *Angew. Chem. Int. Ed.* **2021**, *60*, 191.
- [2] X.-K. He, J. Lu, A.-J. Zhang, Q.-Q. Zhang, G.-Y. Xu, J. Xuan, *Org. Lett.* **2020**, *22*, 5984.
- [3] F. Berger, M. B. Plutschack, J. Rieger, W. Yu, S. Speicher, M. Ho, N. Frank, T. Ritter, *Nature* **2019**, *567*, 223.
- [4] H. Bao, Z. Lin, M. Jin, H. Zhang, J. Xu, B. Chen, W. Li, *Tetrahedron Lett.* **2021**, *66*, 152841.
- [5] J. Yuan, S. Liu, L. Qu, *Adv. Synth. Catal.* **2017**, *359*, 4197.
- [6] K. Yin, R. Zhang, *Synlett* **2018**, *29*, 597.
- [7] Z.-Y. Xue, Y. Jiang, X.-Z. Peng, W.-C. Yuan, X.-M. Zhang, *Adv. Synth. Catal.* **2010**, *352*, 2132.
- [8] S. Paul, H. D. Khanal, C. D. Clinton, S. H. Kim, Y. R. Lee, *Org. Chem. Front.* **2019**, *6*, 231.
- [9] Y.-y. Jiang, G. Dou, L. Zhang, K. Xu, R. D. Little, C. Zeng, *Adv. Synth. Catal.* **2019**, *361*, 5170.
- [10] A. Moazzam, F. Jafarpour, *New J. Chem.* **2020**, *44*, 16692.
- [11] I. I. Roslan, K.-H. Ng, J.-E. Wu, G.-K. Chuah, S. Jaenicke, *J. Org. Chem.* **2016**, *81*, 9167.
- [12] X.-Y. Chen, X.-X. Nie, Y. Wu, P. Wang, *Chem. Commun.* **2020**, *56*, 5058.